Author: "Stojceva-Taneva O" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Stojceva-Taneva O"' showing total 87 results

Start Over Author "Stojceva-Taneva O"

87 results on '"Stojceva-Taneva O"'

1. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Author: Tofte, N. Lindhardt, M. Adamova, K. Bakker, S.J.L. Beige, J. Beulens, J.W.J. Birkenfeld, A.L. Currie, G. Delles, C. Dimos, I. Francová, L. Frimodt-Møller, M. Girman, P. Göke, R. Havrdova, T. Heerspink, H.J.L. Kooy, A. Laverman, G.D. Mischak, H. Navis, G. Nijpels, G. Noutsou, M. Ortiz, A. Parvanova, A. Persson, F. Petrie, J.R. Ruggenenti, P.L. Rutters, F. Rychlík, I. Siwy, J. Spasovski, G. Speeckaert, M. Trillini, M. Zürbig, P. von der Leyen, H. Rossing, P. Zimmermann, S. Rädisch, B. Hävemeier, A. Busmann, A. Wittkop, U. Neuhaus, B. Ax-Smolarski, R. Zieglschmid, V. Bollweber, E. Wölk, H. Curovic, V.R. Tougaard, N.H. Eickhoff, M.K. Pilemann-Lyberg, S. Winther, S.A. Rosenlund, S.V. Hansen, T.W. von Scholten, B.J. Hansen, C.S. Zobel, E.H. Laursen, J.C. Theilade, S. Jelstrup, L. Juhl, T.R. Riis, D. Hermann, J.A. Lundgaard, A.G. Halkjær, M.L.D. Aabo, L. Frost Lerche, T. Lajer, M. Stefansen, R.J. Campbell, M.A. Durban, A. Raad, J. Prigge, M. Schiemann, M. Wilson, R. Kean, S. Douglas, E. Surtees, P. Gant, C. Yeung, S.M.H. Hagedoorn, I. Flynn, J. Galloway, J. Brooksbank, K. Aparicio, C. Iliev, I.P. Nones, F. Lo Bue, F. Melacini, D. Cugini, D. Prandini, S. Lecchi, V. Yakymchuk, S. Gherardi, G. Villa, A. Villa, D. Gaspari, F. Cannata, A.N. Ferrari, S. Stucchi, N. Albrechtová, Š. Eldeik, E. Amanaki, R. Fernandez-Fernandez, B. Sanchez-Rodriguez, J. Vázquez, C. Sanz, A.B. Sanchez-Niño, M.D. Ramos, A.M. Gonzalo, M.Á. Schmidt, U. Selim, G. Gjorgovski, T. Stratrova, S.S. Stojceva-Taneva, O. Schutten-Westerneng, P. Wierbos, B. Huvers, F. De Bruin, A.K. Lapauw, B. de Man, E. Rokegem, K. Inion, S. Kreutzmann, K. Dewettinck, I. Boukens-de Graaf, C. Clerc-de Jong, F. Entius, J. Nannings, M. van Steenderen, S. Petry, F.W. Kilic, C. PRIORITY investigators
Abstract: Background: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. Methods: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. Findings: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0–3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80–3·42; p
Published: 2020

2. A MULTI-BIOMARKER APPROACH FOR THE PREDICTION OF CARDIOVASCULAR MORTALITY IN HEMODYALISIS PATIENTS: P186 (294)

Author: Selim, G., Stojceva-Taneva, O., Gelev, S., Stojcev, N., Dzekova, P., Trajcevska, L., Asani, A., Busletic, I., Pavleska, S., and Sikole, A.
Published: 2010

3. SUCCESSFUL PREGNANCY IN A 43 YEAR-OLD WOMAN WHO UNDERGO LONG-TERM HEMODIALYSIS: P185 (293)

Author: Selim, G., Stojceva-Taneva, O., Gelev, S., Stojcev, N., Amitov, V., Adamova, G., and Sikole, A.
Published: 2010

4. Lipids, protein intake, and progression of diabetic nephropathy

Author: Stojceva-Taneva, O., Polenakovic, M., Grozdanovski, R., and Sikole, A.
Published: 2001

5. INITIATION OF CHRONIC HEMODIALYSIS IN DIABETIC PATIENTS - THE IMPORTANCE OF WEEKLY UREA CLEARANCE

Author: Stojceva-Taneva, O, Grozdanovski, R, Gelev, S, and Zafirovska, K.
Published: 1999

6. EPO RESPONSE RELATED TO AGE AND GENDER IN PATIENTS WITH CHRONIC RENAL FAILURE

Author: Sikole, A, Spasovski, G, Polenakovik, M, Stojceva-Taneva, O, Stojkovski, Lj, and Grozdanovski, R
Published: 1999

7. IS WEEKLY UREA CLEARANCE RELIABLE PARAMETER FOR INITIATION CHRONIC HEMODIALYSIS?

Author: Grozdanovski, R, Stojceva-Taneva, O, Ivanovski, N, Cakalaroski, K, and Oncevski, A
Published: 1999

8. Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients

Author: Markoska, K, Pejchinovski, M, Pontillo, C, Zurbig, P, Jacobs, L, Smith, A, Masin-Spasovska, J, Stojceva-Taneva, O, Polenakovic, M, Magni, F, Mischak, H, Spasovski, G, Markoska, K, Pejchinovski, M, Pontillo, C, Zurbig, P, Jacobs, L, Smith, A, Masin-Spasovska, J, Stojceva-Taneva, O, Polenakovic, M, Magni, F, Mischak, H, and Spasovski, G
Abstract: Background. An improvement in the glomerular filtration rate (GFR) of chronic kidney disease patients has been an underestimated clinical outcome. Although this may be considered as an unexpected disease course, it may provide some insights into possible mechanisms underlying disease remission and/or regression. Therefore, our aim was to identify urinary peptide biomarkers associated with an improvement in estimated GFR (eGFR) over time and to improve patient stratification. Methods. Capillary electrophoresis coupled with mass spectrometry (CE-MS) was employed to evaluate the urine peptidome of patients with different types of renal diseases. In total, 376 patients with a slope/year between 1.5% and 1.5% were designated as non-progressors or stable, while 177 patients with a>5% slope/ year were designated as patients with an improved eGFR for state-of-art biomarker discovery and validation. Results. We detected 384 significant peptide fragments by comparing the CE-MS data of the stable patients and those with improved renal function in our development cohort. Of these 384, a set of 141 peptides with available amino acid sequence information were used to generate a support vector machinebased classification panel. The biomarker panel was applied to our validation cohort, achieving a moderate area under the curve (AUC) value of 0.85 (81% sensitivity and 81% specificity). The majority of the peptides (78%) from the diagnostic panel arose fromdifferent types of collagen. Conclusions. We have developed a panel of urinary peptide markers able to discriminate those patients predisposed to improve their kidney function over time and possibly be treated with more specific or less aggressive therapy
Published: 2018

9. Brain Natriuretic Peptide between Traditional and Nontraditional Risk Factors in Hemodialysis Patients: Analysis of Cardiovascular Mortality in a Two-Year Follow-Up

Author: B Zafirovska-Ivanovska, P. Dzekova, Gelev S, Stojceva-Taneva O, Goce Spasovski, A. Sikole, L Georgievska-Ismail, L. Trajcevska, S Trojacanec-Piponska, and Selim G
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, medicine.drug_class, medicine.medical_treatment, Kaplan-Meier Estimate, Young Adult, Renal Dialysis, Risk Factors, Internal medicine, Natriuretic Peptide, Brain, Natriuretic peptide, medicine, Humans, Prospective Studies, Young adult, Prospective cohort study, Aged, Proportional Hazards Models, Cardiovascular mortality, Aged, 80 and over, biology, business.industry, Proportional hazards model, C-reactive protein, General Medicine, Middle Aged, Brain natriuretic peptide, C-Reactive Protein, ROC Curve, Cardiovascular Diseases, Nephrology, Area Under Curve, biology.protein, Cardiology, Kidney Failure, Chronic, Female, Hemodialysis, business, Biomarkers, hormones, hormone substitutes, and hormone antagonists, Follow-Up Studies
Abstract: Background: The ability of brain natriuretic peptide (BNP) together with other traditional and nontraditional risk factors to predict cardiovascular (CV) mortality in hemodialysis (HD) patients has not been well established. The aim of this prospective study was to determine the predictive cutoff values of baseline measurement of BNP along with the known CV disease risk factors to predict all-cause and CV mortality in HD patients. Methods: BNP concentration before HD was measured in 125 prevalent HD patients (age 53.0 ± 13.5 years, HD vintage 75.2 ± 61.0 months). In addition, several traditional CV risk factors (blood pressure, dyslipidemia, diabetes mellitus, body mass index, left ventricular hypertrophy) and uremia/dialysis-related CV risk factors (anemia, calcium and phosphate impairment, malnutrition, inflammation, ultrafiltration, HD duration, Kt/V) were examined. Results: During the 2-year follow-up, we lost 28 out of 125 patients (22.5%), with CV disease (65.7%) being the main cause of mortality. The cutoff point for BNP, as predictor of the clinical outcome, according to the ROC curve was 1,194 pg/ml for CV mortality with sensitivity and specificity of 63 and 65%, respectively (AUC 0.61 and confidence interval (CI) 95% 0.47–0.75). Kaplan-Meier analysis showed that all-cause (log-rank, p = 0.002) and CV mortality (log-rank, p = 0.001) were the cause of a significantly lower survival in patients with a mean BNP >1,200 pg/ml. The univariate Cox regression analysis found the following factors to be predictors of all-cause mortality: hemoglobin (1.78 mmol/l), albumin (1,200 pg/ml) and cardiac ejection fraction (≤55%). The multivariate Cox regression analyses demonstrated that only CRP ≧10 mg/l with a hazard ratio (HR) 6.82 (CI 95% 1.86–24.9, p = 0.004) and BNP >1,200 pg/ml with HR 5.79 (CI 95% 1.58–21.3, p = 0.004) were predictors of all-cause mortality. BNP >1,200 pg/ml with HR 13.52 (CI 95% 1.68–108.9, p = 0.014) was found to be an even stronger predictor of CV mortality than CRP ≧10 mg/l with HR 6.53 (CI 95% 1.35–31.6, p = 0.020). Conclusions: Our study pointed out that BNP >1,200 pg/ml as a marker of cardiac dysfunction and CRP ≧10 mg/l as a marker of inflammation identify HD patients at increased risk of CV mortality.
Published: 2011
Full Text: View/download PDF

10. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review

Author: Brück, K, Jager, Kj, Dounousi, E, Kainz, A, Nitsch, D, Ärnlöv, J, Rothenbacher, D, Browne, G, Capuano, V, Ferraro, Pm, Ferrieres, J, Gambaro, G, Guessous, I, Hallan, S, Kastarinen, M, Navis, G, Gonzalez, Ao, Palmieri, L, Romundstad, S, Spoto, B, Stengel, B, Tomson, C, Tripepi, G, Völzke, H, Wiȩcek, A, Gansevoort, R, Schöttker, B, Wanner, C, Vinhas, J, Zoccali, C, Van Biesen, W, Stel, Vs, Jousilahti, P, Helmer, C, Metzger, M, Ruidavets, Jb, Bongard, V, Koenig, W, Denkinger, Md, Brenner, H, Saum, Ku, Nauck, M, Stracke, S, Perry, I, Eustace, J, Lupo, Antonio, Donfrancesco, C, Palleschi, S, Lamaida, N, Capuano, E, Sinkeler, S, Wolffenbuttel, Bh, Bakker, Sj, Aasarød, K, Holmen, J, Chudek, J, Malgorzata, M, Gardete Correia, L, Raposo, Jf, de Francisco, Al, Gayoso Diz, P, Nerpin, E, Lind, L, Bochud, M, Gaspoz, Jm, Fletcher, A, Roderick, P, Van Pottelbergh, G, Van Der Tol, A, Hadjadj, S, and Stojceva Taneva, O.
Subjects: Renal Insufficiency, Chronic/epidemiology/physiopathology, CKD-EPI, urologic and male genital diseases, GLOMERULAR-FILTRATION-RATE, Biomarkers/analysis, systematic review, Epidemiology, Urologi och njurmedicin, Medicine and Health Sciences, Prevalence, Settore MED/14 - NEFROLOGIA, GENERAL-POPULATION, education.field_of_study, biology, CARDIOVASCULAR RISK, Chronic renal disease, ASSOCIATION, ELDERLY POPULATION, female genital diseases and pregnancy complications, Europe, Systematic review, Nephrology, Calibration, epidemiology, Glomerular Filtration Rate, Adult, medicine.medical_specialty, Population, MEDLINE, Renal function, CKD-EPI equation, ALL-CAUSE, Sampling Studies, Europe/epidemiology, CKD, CKD-EPI equation, MDRD, epidemiology, systematic review, Present Clinical Status, Epidemiological Implications and Molecular Basis, CYSTATIN-C, medicine, CKD, Urology and Nephrology, Humans, Renal Insufficiency, Chronic, Intensive care medicine, education, ddc:613, Transplantation, SERUM CREATININE, business.industry, MDRD, Klinisk medicin, medicine.disease, Cystatin C, biology.protein, Clinical Medicine, CHRONIC RENAL-DISEASE, business, Biomarkers, Kidney disease
Abstract: BACKGROUND: Many publications report the prevalence of chronic kidney disease (CKD) in the general population. Comparisons across studies are hampered as CKD prevalence estimations are influenced by study population characteristics and laboratory methods. METHODS: For this systematic review, two researchers independently searched PubMed, MEDLINE and EMBASE to identify all original research articles that were published between 1 January 2003 and 1 November 2014 reporting the prevalence of CKD in the European adult general population. Data on study methodology and reporting of CKD prevalence results were independently extracted by two researchers. RESULTS: We identified 82 eligible publications and included 48 publications of individual studies for the data extraction. There was considerable variation in population sample selection. The majority of studies did not report the sampling frame used, and the response ranged from 10 to 87%. With regard to the assessment of kidney function, 67% used a Jaffe assay, whereas 13% used the enzymatic assay for creatinine determination. Isotope dilution mass spectrometry calibration was used in 29%. The CKD-EPI (52%) and MDRD (75%) equations were most often used to estimate glomerular filtration rate (GFR). CKD was defined as estimated GFR (eGFR)
Published: 2015

11. Hypertension and progression of nephropathy in diabetic and non-diabetic chronic kindney disease patients

Author: Stojceva-Taneva, O, Selim, G, Stojkovski, L, and Ivanovski, N
Subjects: urogenital system, Original Article, urologic and male genital diseases, female genital diseases and pregnancy complications
Abstract: Hypertension is associated with more rapid progression of chronic kidney disease. Several studies have shown that treating hypertension in patients with chronic kidney disease and proteinuria may attenuate the decline in glomerular filtration rate.The study evaluates the prevalence of hypertension and its association with chronic kidney disease progression in patients without and with diabetic nephropathy.Patients with CKD stage 2-4 were followed up by a nephrologist for 12-52 months. A total of 137 patients were included in the study, 70 with non-diabetic CKD and 67 with type 2 diabetes and diabetic nephropathy. Demographic and clinical parameters were recorded at initiation and during follow-up. Glomerular filtration rate was estimated by the Cockroft-Gault formula and progression of CKD by the slope of the estimated GFR decline.Out of 70 patients in the non-diabetic group, 34 were males, (mean age 50.37+/-12.2 years). Out of 67 diabetic patients, 30 were (males, mean age 57.8+/-8.4 years). 77% in the non-diabetic group had SBP above 140 mmHg. The higher SBP was associated with older age, (53.16+/-10.8 vs 40.9+/-12.2 years, p0.0001). Diastolic blood pressure above 90 was present in 73%. Pulse pressure above 80 had 5.7% and was associated with older age (p0.02). Progression of chronic kidney disease correlated inversely with age, and positively with diastolic blood pressure and proteinuria (p=0.005, p=0.019 and p=0.02 respectively). Multiple regression analysis showed that only younger age and higher proteinuria were predictive for chronic kidney disease progression (p=0.00002). 6% of pts in the diabetic group had SBP below 140, 19% between 140 and 160, and 75% above 160 mmHg. Diastolic blood pressure below 80 had only 6% of patients, between 80 and 90 had 37% and above 90 mmHg had 57%. Pulse pressure below 80 mmHg had 55% and it was correlated positively with age, p=0.009. Progression of chronic kidney disease in the diabetic group correlated positively with mean arterial pressure, systolic blood pressure and proteinuria, (p=0.017, 0.036 and 0.000000 respectively) and inversely with age (p=0.0003). Multiple regression analysis showed that proteinuria, age and SBP were the only predictors for chronic kidney disease progression in diabetics.Isolated systolic hypertension predominates the older age groups, proteinuria and age significantly correlate with GFR decline in both groups, and SBP is associated with more rapid progression of CKD in the diabetic patients.
Published: 2007

12. Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients

Author: Selim, G, Stojceva-Taneva, O, Ivanovski, N, Zafirovska, K, Sikole, A, Trajcevska, L, Asani, A, and Polenakovic, M
Subjects: Original Article
Abstract: Cardiovascular diseases are the most common causes of death among hemodialysis (HD) patients, yet the risk factors for these events have not been well established. Our study objective was to determine predictors of cardiovascular mortality, considering the non-traditional/disease-related and treatment-related/ cardiovascular risk factor in HD patients.Disease-related cardiovascular risk factors, such as anaemia, calcium-phosphate disorders, nutrition-inflammation and treatment/dialysis-related cardiovascular risk factors such as HD dose, using the index Kt/V were analyzed in 214 patients on HD. Mortality was monitored prospectively over a two year period.Fifty-three of the 214 HD patients died during the follow-up period and the main cause of death was cardiovascular events (56.6%), followed by infection/sepsis (26.4%). The patients who died were significantly older than those alive, had significantly lower serum levels of hemoglobin (Hb), albumin and Kt/V. Serum levels of calcium, C-reactive protein (CRP) and fibrinogen were significantly higher in patients who died during the follow-up period. Kaplan-Meier analysis showed that the all cause and cardiovascular mortality was considerably higher in patients with Hb110 g/l, albumin40 g/l, CRP8 mg/l and spKt/V1.2 (log rank, p=0.000/p=0.000, p=0.000/ p=0.001, p=0.000/p=0.000, p=0.000/p=0.000), respectively. No difference in cardiovascular mortality was observed between the fibrinogen4 g/llevels. High CRP, low Hb levels and low spKt/V were significant predictors of all-cause mortality, but low albumin and high fibrinogen levels were not in the Cox proportional hazards analysis. When only cardiovascular mortality was entered into the Cox model, high CRP and low Hb levels were the only significant predictors for mortality.It can be concluded that, inflammation (elevated CRP) and anaemia (decreased Hb), were identified as significant independent non-traditional, disease-related cardiovascular risk factors that predict cardiovascular mortality in HD patients.
Published: 2007

13. DIALYSIS. PATHOPHYSIOLOGY AND CLINICAL STUDIES

Author: Humalda, J. K., primary, Assa, S., additional, Navis, G. J., additional, Franssen, C. F. M., additional, De Borst, M. H., additional, Ogawa, H., additional, Ota, Y., additional, Watanabe, T., additional, Watanabe, Y., additional, Nishii, H., additional, Sato, A., additional, Waniewski, J., additional, Debowska, M., additional, Wojcik-Zaluska, A., additional, Ksiazek, A., additional, Zaluska, W., additional, Guastoni, C. M., additional, Turri, C., additional, Toma, L., additional, Rombola, G., additional, Frattini, G., additional, Romei Longhena, G., additional, Teatini, U., additional, Siriopol, D.-C., additional, Stuard, S., additional, Ciolan, A., additional, Mircescu, G., additional, Raluca, D., additional, Nistor, I., additional, Covic, A., additional, De Roij Van Zuijdewijn, C. L., additional, Chapdelaine, I., additional, Nube, M. J., additional, Blankestijn, P. J., additional, Bots, M. L., additional, Konings, S. J., additional, Van Den Dorpel, M. A., additional, Van Der Weerd, N. C., additional, Ter Wee, P. M., additional, Grooteman, M. P., additional, Djuric, P. S., additional, Jankovic, A., additional, Tosic, J., additional, Bajcetic, S., additional, Damjanovic, T., additional, Popovic, J., additional, Dimkovic, N., additional, Marinkovic, J., additional, Djuric, Z., additional, Knezevic, V., additional, Lazarevic, T., additional, Ljubenovic, S., additional, Markovic, R., additional, Rabrenovic, V., additional, Djukanovic, L., additional, Radovic Maslarevic, V., additional, Mathrani, V., additional, Drew, P., additional, Chess, J. I., additional, Williams, A. I., additional, Robertson, S., additional, Jibani, M., additional, Aithal, V. I., additional, Kumwenda, M., additional, Roberts, G., additional, Mikhail, A. I., additional, Grzegorzewska, A. E., additional, Ostromecki, G., additional, Mostowska, A., additional, Sowi ska, A., additional, Jagodzi ski, P. P., additional, Wu, H.-Y., additional, Chen, H.-Y., additional, Hsu, S.-P., additional, Pai, M.-F., additional, Yang, J.-Y., additional, Peng, Y.-S., additional, Hirose, M., additional, Hasegawa, T., additional, Kaneshima, N., additional, Sasai, F., additional, Komukai, D., additional, Takahashi, K., additional, Koiwa, F., additional, Shishido, K., additional, Yoshimura, A., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Dzekova-Vidimliski, P., additional, Trajceska, L., additional, Petronievic, Z., additional, Gelev, S., additional, Amitov, V., additional, Sikole, A., additional, Moon, S. J., additional, Yoon, S. Y., additional, Shin, D. H., additional, Lee, J. E., additional, Kim, H.-J., additional, Park, H.-C., additional, Hadjiyannakos, D., additional, Filiopoulos, V., additional, Loukas, G., additional, Pagonis, S., additional, Andriopoulos, C., additional, Drakou, A., additional, Vlassopoulos, D., additional, Catarino, C., additional, Cunha, P., additional, Ribeiro, S., additional, Rocha-Pereira, P., additional, Reis, F., additional, Sameiro-Faria, M., additional, Miranda, V., additional, Bronze-Rocha, E., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, De Mauri, A., additional, Brambilla, M., additional, Chiarinotti, D., additional, Lizio, D., additional, Matheoud, R., additional, Conti, N., additional, Conte, M. M., additional, Carriero, A., additional, De Leo, M., additional, Karpetas, A. V., additional, Sarafidis, P. A., additional, Georgianos, P. I., additional, Koutroumpas, G., additional, Divanis, D., additional, Vakianis, P., additional, Tzanis, G., additional, Raptopoulou, K., additional, Protogerou, A., additional, Stamatiadis, D., additional, Syrganis, C., additional, Liakopoulos, V., additional, Efstratiadis, G., additional, Lasaridis, A. N., additional, Tersi, M., additional, Stamatiadis, D. N., additional, Kuczera, P., additional, Adamczak, M., additional, Wiecek, A., additional, Bove, S., additional, Giacon, B., additional, Corradini, R., additional, Prati, E., additional, Brognoli, M., additional, Tommasi, A., additional, Sereni, L., additional, Palladino, G., additional, Moriya, H., additional, Mochida, Y., additional, Ishioka, K., additional, Oka, M., additional, Maesato, K., additional, Hidaka, S., additional, Ohtake, T., additional, Kobayashi, S., additional, Moura, A., additional, Madureira, J., additional, Alija, P., additional, Fernandes, J. C., additional, Oliveira, J. G., additional, Lopez, M., additional, Filgueiras, M., additional, Amado, L., additional, Vieira, M., additional, Seok, J.-H., additional, Choi, H. Y., additional, Ha, S. K., additional, Park, H. C., additional, Bossola, M., additional, Laudisio, A., additional, Antocicco, M., additional, Tazza, L., additional, Colloca, G., additional, Tosato, M., additional, Zuccala, G., additional, Ettema, E. M., additional, Kuipers, J., additional, Groen, H., additional, Gansevoort, R. T., additional, Stade, K., additional, Bakker, S. J. L., additional, Gaillard, C. A. J. M., additional, Westerhuis, R., additional, Bacchetta, J., additional, Couchoud, K., additional, Semlali, S., additional, Sellier-Leclerc, A.-L., additional, Bertholet-Thomas, A., additional, Cartier, R., additional, Cochat, P., additional, Ranchin, B., additional, Kim, J. C., additional, Park, K., additional, Van Ende, C., additional, Wilmes, D., additional, Lecouvet, F. E., additional, Labriola, L., additional, Cuvelier, R., additional, Van Ingelgem, G., additional, Jadoul, M., additional, Doriana, C., additional, David, P., additional, Capurro, F., additional, Brustia, M., additional, Ruva, C. E., additional, Giungi, S., additional, Di Stasio, E., additional, Lemesch, S., additional, Leber, B., additional, Horvath, A., additional, Ribitsch, W., additional, Schilcher, G., additional, Zettel, G., additional, Tawdrous, M., additional, Rosenkranz, A. R., additional, Stadlbauer-Kollner, V., additional, Matsushima, H., additional, Oyama, A., additional, Bosch Benitez-Parodi, E., additional, Baamonde Laborda, E., additional, Batista Garcia, F., additional, Perez Suarez, G., additional, Anton Perez, G., additional, Garcia Canton, C., additional, Toledo Gonzalez, A., additional, Lago Alonso, M. M., additional, Checa Andres, M. D., additional, Cobo, G., additional, Di Gioia, C., additional, Camacho, R., additional, Garcia Lacalle, C., additional, Ortega, O., additional, Rodriguez, I., additional, Herrero, J., additional, Oliet, A., additional, Ortiz, M., additional, Mon, C., additional, Vigil, A., additional, Gallar, P., additional, Pellu, V., additional, Nebiolo, P. E., additional, Sasaki, K., additional, Yamguchi, S., additional, Hesaka, A., additional, Iwahashi, E., additional, Sakai, S., additional, Fujimoto, T., additional, Minami, S., additional, Fujita, Y., additional, Yokoyama, K., additional, Shutov, E., additional, Ryabinskya, G., additional, Lashutin, S., additional, Gorelova, E., additional, Volodicheva, E., additional, Podesta, M. A., additional, Cancarini, G., additional, Cucchiari, D., additional, Montanelli, A., additional, Badalamenti, S., additional, Graziani, G., additional, Distasio, E., additional, Pchelin, I., additional, Shishkin, A., additional, Fedorova, Y., additional, Kao, C.-C., additional, Chu, T.-S., additional, Tsai, T.-J., additional, Wu, K.-D., additional, Wu, M.-S., additional, Raikou, V., additional, Kaisidis, P., additional, Tsamparlis, E., additional, Kanellopoulos, P., additional, Boletis, J., additional, Ueda, A., additional, Hirayama, A., additional, Owada, S., additional, Nagai, K., additional, Saito, C., additional, and Yamagata, K., additional
Published: 2014
Full Text: View/download PDF

14. DIALYSIS CARDIOVASCULAR COMPLICATIONS 1

Author: Wheeler, D. C., primary, Abdalla, S., additional, Chertow, G., additional, Parfrey, P., additional, Herzog, C., additional, Mikolasevic, I., additional, Racki, S., additional, Lukenda, V., additional, Milic, S., additional, Devcic, B., additional, Orlic, L., additional, Suttorp, M. M., additional, Hoekstra, T., additional, Ocak, G., additional, Van Diepen, A. T. N., additional, Ott, I., additional, Mittelman, M., additional, Rabelink, T. J., additional, Krediet, R. T., additional, Dekker, F. W., additional, Simone, S., additional, Dell'Oglio, M. P. S., additional, Ciccone, M., additional, Corciulo, R., additional, Castellano, G., additional, Balestra, C., additional, Grandaliano, G., additional, Gesualdo, L., additional, Pertosa, G., additional, Nishida, M., additional, Ando, M., additional, Karasawa, K., additional, Iwamoto, Y., additional, Tsuchiya, K., additional, Nitta, K., additional, Krzanowski, M., additional, Janda, K., additional, Gajda, M., additional, Dumnicka, P., additional, Fedak, D., additional, Lis, G., additional, Ja kowski, P., additional, Litwin, J. A., additional, Su owicz, W., additional, Freitas, G. R., additional, Silva, V. B., additional, Abensur, H., additional, Luders, C., additional, Pereira, B. J., additional, Castro, M. C., additional, Oliverira, R. B., additional, Moyses, R. M., additional, Elias, R. M., additional, Silva, B. C., additional, Tekce, H., additional, Ozturk, S., additional, Aktas, G., additional, Kin Tekce, B., additional, Erdem, A., additional, Ozyasar, M., additional, Taslamacioglu Duman, T., additional, Yazici, M., additional, Kirkpantur, A., additional, Balci, M. M., additional, Turkvatan, A., additional, Afsar, B., additional, Alkis, M., additional, Mandiroglu, F., additional, Voroneanu, L., additional, Siriopol, D., additional, Nistor, I., additional, Apetrii, M., additional, Hogas, S., additional, Onofriescu, M., additional, Covic, A., additional, An, W. S., additional, Kim, S. E., additional, Son, Y. K., additional, Oh, Y. J., additional, Gelev, S., additional, Toshev, S., additional, Trajceska, L., additional, Selim, G., additional, Dzekova, P., additional, Shikole, A., additional, Park, J., additional, Lee, J. S., additional, Shin, E.-S., additional, Ann, S. H., additional, Kim, S.-J., additional, Chung, H. C., additional, Sulowicz, W., additional, Elewa, U., additional, Bichari, W., additional, Abo-Seif, K., additional, Seferi, S., additional, Rroji, M., additional, Likaj, E., additional, Spahia, N., additional, Barbullushi, M., additional, Thereska, N., additional, Kopecky, C. M., additional, Genser, B., additional, Maerz, W., additional, Wanner, C., additional, Saemann, M. D., additional, Weichhart, T., additional, Sezer, S., additional, Gurlek Demirci, B., additional, Tutal, E., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Ozdemir Acar, F. N., additional, Macunluoglu, B., additional, Atakan, A., additional, Ari Bakir, E., additional, Georgianos, P., additional, Sarafidis, P. A., additional, Stamatiadis, D. N., additional, Liakopoulos, V., additional, Zebekakis, P. E., additional, Papagianni, A., additional, Lasaridis, A. N., additional, Eftimovska - Otovic, N., additional, Babalj-Banskolieva, E., additional, Kostadinska-Bogdanoska, S., additional, Grozdanovski, R., additional, Aono, M., additional, Sato, Y., additional, El Amrani, M., additional, Asserraji, M., additional, Benyahia, M., additional, Lee, Y.-K., additional, Choi, S. R., additional, Cho, A., additional, Kim, J.-K., additional, Choi, M.-J., additional, Kim, S. J., additional, Yoon, J.-W., additional, Koo, J.-R., additional, Kim, H. J., additional, Noh, J.-W., additional, Inagaki, H., additional, Yokota, N., additional, Chiyotanda, S., additional, Fukami, K., additional, Fujimoto, S., additional, Kendi Celebi, Z., additional, Kutlay, S., additional, Sengul, S., additional, Nergizoglu, G., additional, Erturk, S., additional, Ates, K., additional, Vishnevskii, K. A., additional, Rumyantsev, A. S., additional, Zemchenkov, A. Y., additional, Smirnov, A. V., additional, Reinhardt, B., additional, Knaup, R., additional, Esteve Simo, V., additional, Carneiro Oliveira, J., additional, Moreno Guzman, F., additional, Fulquet Nicolas, M., additional, Pou Potau, M., additional, Saurina Sole, A., additional, Duarte Gallego, V., additional, Ramirez De Arellano Serna, M., additional, Turkmen, K., additional, Demirtas, L., additional, Akbas, E. M., additional, Bakirci, E. M., additional, Buyuklu, M., additional, Timuroglu, A., additional, Georgianos, P. I., additional, Karpetas, A., additional, Taira, T., additional, Nohtomi, K., additional, Takemura, T., additional, Chiba, T., additional, Hirano, T., additional, Chang, C.-T., additional, Huang, C.-C., additional, Chen, C.-J., additional, Mohamed, A., additional, Kanai, H., additional, Tamura, Y., additional, Kaizu, Y., additional, Kali, A., additional, Yayar, O., additional, Erdogan, B., additional, Eser, B., additional, Ercan, Z., additional, Buyukbakkal, M., additional, Merhametsiz, O., additional, Haspulat, A., additional, Yildirim, T., additional, Bozkurt, B., additional, Ayli, M. D., additional, Gokustun, D., additional, Markaki, A., additional, Grammatikopoulou, M., additional, Fragkiadakis, G., additional, Stylianou, K., additional, Venyhaki, M., additional, Chatzi, V., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Dzekova-Vidimliski, P., additional, Petronievic, Z., additional, Sikole, A., additional, Moyseyenko, V., additional, Nykula, T., additional, Fernandes, R. T., additional, Barreto, D. V., additional, Rodrigues, G. G. C., additional, Misael, A., additional, Branco-Martins, C. T., additional, and Barreto, F. C., additional
Published: 2014
Full Text: View/download PDF

15. Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report

Author: Noordzij, M., primary, Kramer, A., additional, Abad Diez, J. M., additional, Alonso de la Torre, R., additional, Arcos Fuster, E., additional, Bikbov, B. T., additional, Bonthuis, M., additional, Bouzas Caamano, E., additional, ala, S., additional, Caskey, F. J., additional, Castro de la Nuez, P., additional, Cernevskis, H., additional, Collart, F., additional, Diaz Tejeiro, R., additional, Djukanovic, L., additional, Ferrer-Alamar, M., additional, Finne, P., additional, Garcia Bazaga, M. d. l. A., additional, Garneata, L., additional, Golan, E., additional, Gonzalez Fernandez, R., additional, Heaf, J. G., additional, Hoitsma, A., additional, Ioannidis, G. A., additional, Kolesnyk, M., additional, Kramar, R., additional, Lasalle, M., additional, Leivestad, T., additional, Lopot, F., additional, van de Luijtgaarden, M. W. M., additional, Macario, F., additional, Magaz, A., additional, Martin Escobar, E., additional, de Meester, J., additional, Metcalfe, W., additional, Ots-Rosenberg, M., additional, Palsson, R., additional, Pinera, C., additional, Pippias, M., additional, Prutz, K. G., additional, Ratkovic, M., additional, Resi , H., additional, Rodriguez Hernandez, A., additional, Rutkowski, B., additional, Spustova, V., additional, Stel, V. S., additional, Stojceva-Taneva, O., additional, Suleymanlar, G., additional, Wanner, C., additional, and Jager, K. J., additional
Published: 2014
Full Text: View/download PDF

16. CKD pathophysiology and complications

Author: Vlahu, C. A., primary, Vogt, L., additional, Struijk, D. G., additional, Vink, H., additional, Krediet, R. T., additional, Kurita, N., additional, Fujii, A., additional, Kotera, N., additional, Tanaka, M., additional, Tanaka, S., additional, Miyairi, T., additional, Sugimoto, T., additional, Mori, M., additional, Fukuhara, S., additional, Mise, N., additional, Pasch, A., additional, Farese, S., additional, Schlieper, G., additional, Floege, J., additional, Uehlinger, D., additional, Jahnen-Dechent, W., additional, Mose, F. H., additional, Vase, H., additional, Larsen, T., additional, Kancir, A. S. P., additional, Kosierkiewicz, R., additional, Jonczy, B., additional, Hansen, A. B., additional, Oczachowska-Kulik, A. E., additional, Thomsen, I. M., additional, Bech, J. N., additional, Pedersen, E. B., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Georgievska-Ismail, L., additional, Gelev, S., additional, Dzekova-Vidimliski, P., additional, Trajceska, L., additional, Petronievic, Z., additional, and Sikole, A., additional
Published: 2013
Full Text: View/download PDF

17. Clinical Nephrology - Epidemiology II

Author: Agnes, H., primary, Kalman, P., additional, Jozsef, A., additional, Henrik, B., additional, Mucsi, I., additional, Kamata, K., additional, Sano, T., additional, Naito, S., additional, Okamoto, T., additional, Okina, C., additional, Kamata, M., additional, Murano, J., additional, Kobayashi, K., additional, Uchida, M., additional, Aoyama, T., additional, Takeuchi, Y., additional, Nagaba, Y., additional, Sakamoto, H., additional, Torino, C., additional, Panuccio, V., additional, Clementi, A., additional, Garozzo, M., additional, Bonanno, G., additional, Boito, R., additional, Natale, G., additional, Cicchetti, T., additional, Chippari, A., additional, Logozzo, D., additional, Alati, G., additional, Cassani, S., additional, Sellaro, A., additional, D'arrigo, G., additional, Tripepi, G., additional, Roberta, A., additional, Postorino, M., additional, Mallamaci, F., additional, Zoccali, C., additional, Buonanno, E., additional, Brancaccio, S., additional, Fimiani, V., additional, Napolitano, P., additional, Spadola, R., additional, Morrone, L., additional, DI Iorio, B., additional, Russo, D., additional, Betriu, A., additional, Martinez-Alonso, M., additional, Vidal, T., additional, Valdivielso, J., additional, Fernandez, E., additional, Bernadette, F., additional, Jean-Baptiste, B., additional, Frimat, L., additional, Madala, N. D., additional, Thusi, G. P., additional, Sibisi, N., additional, Mazibuko, B. G., additional, Assounga, A. G. H., additional, Tsai, N.-C., additional, Wang, H.-H., additional, Chen, Y.-C., additional, Hung, C.-C., additional, Hwang, S.-J., additional, Chen, H.-C., additional, Branco, P., additional, Adragao, T., additional, Birne, R., additional, Martins, A. R., additional, Vizinho, R., additional, Gaspar, A., additional, Grilo, M. J., additional, Barata, J. D., additional, Bonhorst, D., additional, Adragao, P., additional, Kim, J. S., additional, Yang, J. W., additional, Kim, M. K., additional, Choi, S. O., additional, Han, B. G., additional, Nathalie, N., additional, Sunny, E., additional, Glorieux, G., additional, Daniela, B., additional, Fellype, B., additional, Sophie, L., additional, Horst D, L., additional, Ziad, M., additional, Raymond, V., additional, Yanai, M., additional, Okada, K., additional, Takeuchi, K., additional, Nitta, K., additional, Takahashi, S., additional, Morena, M., additional, Jaussent, I., additional, Halkovich, A., additional, Dupuy, A.-M., additional, Bargnoux, A.-S., additional, Chenine, L., additional, Leray-Moragues, H., additional, Klouche, K., additional, Vernhet, H., additional, Canaud, B., additional, Cristol, J.-P., additional, Shutov, A., additional, Serov, V., additional, Kuznetsova, J., additional, Menzorov, M., additional, Serova, D., additional, Petrescu, L., additional, Zugravu, A., additional, Capusa, C., additional, Stancu, S., additional, Cinca, S., additional, Anghel, C., additional, Timofte, D., additional, Medrihan, L., additional, Ionescu, D., additional, Mircescu, G., additional, Hsu, T.-W., additional, Kuo, K.-L., additional, Hung, S.-C., additional, Tarng, D.-C., additional, Lee, S., additional, Kim, I., additional, Lee, D., additional, Rhee, H., additional, Song, S., additional, Seong, E., additional, Kwak, I., additional, Holzmann, M., additional, Gardell, C., additional, Jeppsson, A., additional, Sartipy, U., additional, Solak, Y., additional, Yilmaz, M. I., additional, Caglar, K., additional, Saglam, M., additional, Yaman, H., additional, Sonmez, A., additional, Unal, H. U., additional, Gok, M., additional, Gaipov, A., additional, Kayrak, M., additional, Eyileten, T., additional, Turk, S., additional, Vural, A., additional, DI Lullo, L., additional, Floccari, F., additional, Rivera, R., additional, Granata, A., additional, D'amelio, A., additional, Logias, F., additional, Otranto, G., additional, Malaguti, M., additional, Santoboni, A., additional, Fiorini, F., additional, Connor, T., additional, Oygar, D., additional, Nitsch, D., additional, Gale, D., additional, Steenkamp, R., additional, Neild, G. H., additional, Maxwell, P., additional, Louise Hogsbro, I., additional, Redal-Baigorri, B., additional, Sautenet, B., additional, Halimi, J. M., additional, Caille, A., additional, Goupille, P., additional, Giraudeau, B., additional, Oguz, Y., additional, Yenicesu, M., additional, Cetinkaya, H., additional, Ishimoto, Y., additional, Ohki, T., additional, Sugahara, M., additional, Kanemitsu, T., additional, Kobayashi, M., additional, Uchida, L., additional, Kotera, N., additional, Tanaka, S., additional, Sugimoto, T., additional, Mise, N., additional, Miyazaki, N., additional, Matsumoto, J., additional, Murata, I., additional, Yoshida, G., additional, Morishita, K., additional, Ushikoshi, H., additional, Nishigaki, K., additional, Ogura, S., additional, Minatoguchi, S., additional, Harvey, R., additional, Ala, A., additional, Banerjee, D., additional, Farmer, C., additional, Irving, J., additional, Hobbs, H., additional, Wheeler, T., additional, Klebe, B., additional, Stevens, P., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Stojcev, N., additional, Gelev, S., additional, Dzekova-Vidimliski, P., additional, Pavleska, S., additional, Sikole, A., additional, Qureshi, A. R., additional, Evans, M., additional, Stendahl, M., additional, Prutz, K. G., additional, Elinder, C. G., additional, Tamagaki, K., additional, Kado, H., additional, Nakata, M., additional, Kitani, T., additional, Ota, N., additional, Ishida, R., additional, Matsuoka, E., additional, Shiotsu, Y., additional, Ishida, M., additional, Mori, Y., additional, Christelle, M., additional, Rognant, N., additional, Evelyne, D., additional, Sophie, F., additional, Laurent, J., additional, Maurice, L., additional, Silverwood, R., additional, Pierce, M., additional, Kuh, D., additional, Savage, C., additional, Ferro, C., additional, Moniek, D. G., additional, De Goeij, M., additional, Nynke, H., additional, Gurbey, O., additional, Joris, R., additional, Friedo, D., additional, Clayton, P., additional, Grace, B., additional, Cass, A., additional, Mcdonald, S., additional, Lorenzo, V., additional, Martin Conde, M., additional, Dusso, A., additional, Valdivielso, J. M., additional, Roggeri, D. P., additional, Cannella, G., additional, Cozzolino, M., additional, Mazzaferro, S., additional, Messa, P., additional, Brancaccio, D., additional, De Souza Faria, R., additional, Fernandes, N., additional, Lovisi, J., additional, Moura Marta, M., additional, Reboredo, M., additional, Do Vale Pinheiro, B., additional, Bastos, M., additional, Hundt, F., additional, Pabst, S., additional, Hammerstingl, C., additional, Gerhardt, T., additional, Skowasch, D., additional, Woitas, R., additional, Lopes, A. A., additional, Silva, L. F., additional, Matos, C. M., additional, Martins, M. S., additional, Silva, F. A., additional, Lopes, G. B., additional, Pizzarelli, F., additional, Dattolo, P., additional, Michelassi, S., additional, Rossi, C., additional, Bandinelli, S., additional, Mieth, M., additional, Mass, R., additional, Ferrucci, L., additional, Parisi, S., additional, Arduino, S., additional, Attini, R., additional, Fassio, F., additional, Biolcati, M., additional, Pagano, A., additional, Bossotti, C., additional, Ferraresi, M., additional, Gaglioti, P., additional, Todros, T., additional, Piccoli, G. B., additional, Salgado, T. M., additional, Arguello, B., additional, Benrimoj, S. I., additional, Fernandez-Llimos, F., additional, Bailey, P., additional, Tomson, C., additional, Ben-Shlomo, Y., additional, Santoro, A., additional, Rucci, P., additional, Mandreoli, M., additional, Caruso, F., additional, Corradini, M., additional, Flachi, M., additional, Gibertoni, D., additional, Rigotti, A., additional, Russo, G., additional, Fantini, M., additional, Mahapatra, H. S., additional, Choudhury, S., additional, Buxi, G., additional, Sharma, N., additional, Gupta, Y., additional, Sekhar, V., additional, Yanagisawa, N., additional, Ando, M., additional, Ajisawa, A., additional, Tsuchiya, K., additional, Janusz, O., additional, Mikolaj, M., additional, Jacek, M., additional, Boleslaw, R., additional, Prakash, S., additional, Coffin, R., additional, Schold, J., additional, Einstadter, D., additional, Stark, S., additional, Rodgers, D., additional, Howard, M., additional, Sehgal, A., additional, Palmer, S., additional, Tong, A., additional, Manns, B., additional, Craig, J., additional, Ruospo, M., additional, Gargano, L., additional, Strippoli, G., additional, Vecchio, M., additional, Petruzzi, M., additional, De Benedictis, M., additional, Pellegrini, F., additional, Ohno, Y., additional, Ishimura, E., additional, Naganuma, T., additional, Kondo, K., additional, Fukushima, W., additional, Mui, K., additional, Inaba, M., additional, Hirota, Y., additional, Sun, X., additional, Jiang, S., additional, Gu, H., additional, Chen, Y., additional, XI, C., additional, Qiao, X., additional, Chen, X., additional, Daher, E., additional, Junior, G. S., additional, Jacinto, C. N., additional, Pimentel, R. S., additional, Aguiar, G. B. R., additional, Lima, C. B., additional, Borges, R. C., additional, Mota, L. P. C., additional, Melo, J. V. L., additional, Melo, S. A., additional, Canamary, V. T., additional, Alves, M., additional, Araujo, S. M. H. A., additional, Huang, Y. K., additional, Rogacev, K., additional, Cremers, B., additional, Zawada, A., additional, Seiler, S., additional, Binder, N., additional, Ege, P., additional, Grosse-Dunker, G., additional, Heisel, I., additional, Hornof, F., additional, Jeken, J., additional, Rebling, N., additional, Ulrich, C., additional, Scheller, B., additional, Bohm, M., additional, Fliser, D., additional, Heine, G. H., additional, Robinson, B., additional, Wang, M., additional, Bieber, B., additional, Fluck, R., additional, Kerr, P. G., additional, Wikstrom, B., additional, Krishnan, M., additional, Nissenson, A., additional, Pisoni, R. L., additional, Mykleset, S., additional, Osthus, T. B., additional, Waldum, B., additional, Os, I., additional, Buttigieg, J., additional, Cassar, A., additional, Farrugia Agius, J., additional, Hara, M., additional, Yamato, M., additional, Yasuda, K., additional, and Sasaki, K., additional
Published: 2012
Full Text: View/download PDF

18. Mineral and bone disease - CKD 5D

Author: Hecking, M., primary, Kainz, A., additional, Bielesz, B., additional, Plischke, M., additional, Beilhack, G., additional, Hoerl, W. H., additional, Sunder-Plassmann, G., additional, Bieglmayer, C., additional, Benchetrit, S., additional, Green, J., additional, Bernheim, J., additional, Golan, E., additional, Oyake, N., additional, Suzuki, K., additional, Itoh, S., additional, Tanabe, K., additional, Fujimori, A., additional, Okada, S., additional, Yamamoto, K., additional, Sakai, M., additional, Kamiura, N., additional, Solenne, P., additional, Guebre-Egziabher, F., additional, Bacchetta, J., additional, Drai, J., additional, Richard, M., additional, Chapurlat, R., additional, Fouque, D., additional, Nowak, Z., additional, Grzegorz, K., additional, Maria, K., additional, Zofia, W., additional, Zamboch, K., additional, Zahalkova, J., additional, Kosatikova, Z., additional, Skypalova, P., additional, Skarda, J., additional, Cunha, J., additional, Boim, M., additional, Ferreira, V., additional, Naves, M., additional, Kikuchi, H., additional, Shimada, H., additional, Takimoto, Y., additional, Karasawa, R., additional, Shimotori, M., additional, Ikarashi, K., additional, Saito, N., additional, Miyazaki, S., additional, Sakai, S., additional, Suzuki, M., additional, Ogata, H., additional, Takeshima, A., additional, Yamamoto, M., additional, Asakura, K., additional, Kato, T., additional, Shishido, K., additional, Koiwa, F., additional, Mizobuchi, M., additional, Kinugasa, E., additional, Akizawa, T., additional, Londrino, F., additional, Corbani, V., additional, Ardini, M., additional, Falqui, V., additional, Zattera, T., additional, Rombola', G., additional, Takeshige, Y., additional, Matsuzaka, K., additional, Ciceri, P., additional, Volpi, E., additional, Brenna, I., additional, Elli, F., additional, Borghi, E., additional, Brancaccio, D., additional, Cozzolino, M., additional, Farrand, K., additional, Copley, J. B., additional, Heise, J., additional, Fridman, M., additional, Keith, M., additional, Silverberg, A., additional, Wilson, R., additional, Poole, L., additional, Jean, G., additional, Bresson, E., additional, Chazot, C., additional, Maduell, F., additional, Arias, M., additional, Sentis, A., additional, Rodriguez, N., additional, Jimenez, S., additional, Alemany, B., additional, Perez, N., additional, Vera, M., additional, Fontsere, N., additional, Carrera, M., additional, Cases, A., additional, Sonikian, M., additional, Miha, T., additional, Skarakis, I., additional, Karatzas, I., additional, Karaitianou, A., additional, Tomanoski, V., additional, Petkovic, D., additional, Curic, I., additional, Hrvacevic, R., additional, Kaperonis, N., additional, Kourvelou, C., additional, Sgantzos, A., additional, Nastou, D., additional, Ntatsis, G., additional, Ziakka, S., additional, Karakasis, F., additional, Nikolopoulos, V., additional, Zoubaniotou, D., additional, Koutsovasili, A., additional, Zagorianakos, A., additional, Kolovos, V., additional, Papagalanis, N., additional, Forni, V., additional, Pruijm, M., additional, Tousset, E., additional, Zweiacker, C., additional, Menetrey, I., additional, Berwert, L., additional, Bullani, R., additional, Cherpillod, A., additional, Gabutti, L., additional, Gauthier, T., additional, Halabi, G., additional, Mathieu, C., additional, Meier, P., additional, Phan, O., additional, Pianca, S., additional, Schoenholzer, C., additional, Teta, D., additional, Von Albertini, B., additional, Vrijens, B., additional, Burnier, M., additional, Kurita, N., additional, Fukagawa, M., additional, Onishi, Y., additional, Yamaguchi, T., additional, Hasegawa, T., additional, Fukuma, S., additional, Kurokawa, K., additional, Fukuhara, S., additional, Urena, P., additional, Bridges, I., additional, Christiano, C., additional, Cournoyer, S., additional, Cooper, K., additional, Farouk, M., additional, Kopyt, N., additional, Rodriguez, M., additional, Zehnder, D., additional, Covic, A., additional, Tominaga, Y., additional, Hiramitsu, T., additional, Yamamoto, T., additional, Nanmoku, K., additional, Matsuda, Y., additional, Tsuzuki, T., additional, Lang, C.-L., additional, Lu, K.-C., additional, Wang, M.-H., additional, Liu, S.-Y., additional, Huang, J.-W., additional, Chiang, C.-K., additional, Hung, K.-Y., additional, Bantis, C., additional, Kouri, N.-M., additional, Tsandekidou, E., additional, Frangidis, S., additional, Tsiandoulas, A., additional, Liakou, E., additional, Bamichas, G., additional, Stangou, M., additional, Papagianni, A., additional, Efstratiadis, G., additional, Natse, T., additional, Memmos, D., additional, Messa, P., additional, Cannella, G., additional, Mazzaferro, S., additional, Yu, X., additional, Bieber, B., additional, Guidinger, M., additional, Yang, X., additional, Tentori, F., additional, Pisoni, R., additional, Qian, J., additional, Chen, N., additional, Yan, Y., additional, Wang, M., additional, Zuo, L., additional, Wang, H., additional, Albert, J., additional, Ramirez, S., additional, Caccetta, F., additional, Caroppo, M., additional, Musio, F., additional, Mudoni, A., additional, Accogli, A., additional, Zacheo, M. D., additional, Nuzzo, V., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Gelev, S., additional, Pusevski, V., additional, Dzekova-Vidimliski, P., additional, Rambabova-Busletic, I., additional, Sikole, A., additional, Esposito, P., additional, Coppo, R., additional, Malberti, F., additional, Dal Canton, A., additional, Moriwaki, K., additional, Komaba, H., additional, Kakuta, T., additional, Cernaro, V., additional, Lupica, R., additional, Donato, V., additional, Lacquaniti, A., additional, Fazio, M. R., additional, Lucisano, S., additional, Buemi, M., additional, Okuno, S., additional, Ishimura, E., additional, Tsuboniwa, N., additional, Norimine, K., additional, Yamakawa, K., additional, Yamakawa, T., additional, Shoji, S., additional, Mori, K., additional, Nishizawa, Y., additional, Inaba, M., additional, Dahaba, M., additional, Seck, S., additional, Cisse, M., additional, Jotoku, Y., additional, Sato, Y., additional, Dimkovic, N., additional, Asicioglu, E., additional, Kahveci, A., additional, Arikan, H., additional, Koc, M., additional, Tuglular, S., additional, Ozener, C., additional, Kido, R., additional, Yamaguch, T., additional, Krasniak, A., additional, Drozdz, M., additional, Chmiel, G., additional, Podolec, P., additional, Pasowicz, M., additional, Kowalczyk-Michalek, M., additional, Sulowicz, W., additional, Perez-Suarez, G., additional, Baamonde, E., additional, Bosch, E., additional, Ramirez, J. I., additional, El Hayek, B., additional, Lago, M. D. M., additional, Garcia, C., additional, Checa, M. D., additional, Hiramatsu, R., additional, Ubara, Y., additional, Salas, K., additional, Vicent, E. S., additional, Gonzalez Oliva, J. C., additional, Fulquet, M., additional, Duarte, V., additional, Pou, M., additional, Saurina, A., additional, Macias, J., additional, Ramirez de Arellano, M., additional, Matias, P., additional, Jorge, C., additional, Mendes, M., additional, Amaral, T., additional, Ferreira, C., additional, Aires, I., additional, Gil, C., additional, Ferreira, A., additional, Arcal, C., additional, Campistol, J. M., additional, Seferi, S., additional, Rroji, M., additional, Likaj, E., additional, Petrela, E., additional, Barbullushi, M., additional, Zeneli, N., additional, Mumajesi, S., additional, Thereska, N., additional, Vulpio, C., additional, Bossola, M., additional, Stigliano, E., additional, Fadda, G., additional, Gueiros, A. P. S., additional, Borba Junior, J. O., additional, Lordsllen, A. B. d. M. D. S., additional, Gueiros, J. E. d. B., additional, Itami, N., additional, Tuneyama, K., additional, Uemura, S., additional, Hamada, H., additional, Takada, J., additional, Takahashi, K., additional, Adamidis, K., additional, Apostolou, T., additional, Pleros, C., additional, Oikonomaki, T., additional, Kyratzi, E., additional, Exarchos, D., additional, Metaxatos, G., additional, Dracopoulos, S., additional, Nikolopoulou, N., additional, Delanaye, P., additional, Dubois, B., additional, Krzesinski, J.-M., additional, Cavalier, E., additional, De la Fuente, V., additional, Gil, M. T., additional, Gutierrez, P., additional, Delgado, P., additional, Ribero, J., additional, Arenas, L., additional, Sezer, S., additional, Tutal, E., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Ozdemir Acar, F. N., additional, Azevedo de Oliveira, R., additional, Carvalho Barreto, F., additional, Dos Reis, L., additional, Cunha Ferreira, J., additional, Maria Leme Britto, Z., additional, Maria Moyses, R., additional, Jorgetti, V., additional, Ozelsancak, R., additional, Gurlek Demirci, B., additional, Torun, D., additional, Veljancic, L., additional, Radojevic, M., additional, Paunic, Z., additional, Vavic, N., additional, Obrencevic, K., additional, Kovacevic, Z., additional, and Pejovic, J., additional
Published: 2012
Full Text: View/download PDF

19. AKI - Clinical

Author: Gok Oguz, E., primary, Olmaz, R., additional, Turgutalp, K., additional, Muslu, N., additional, Sungur, M. A., additional, Kiykim, A., additional, Van Biesen, W., additional, Vanmassenhove, J., additional, Glorieux, G., additional, Vanholder, R., additional, Chew, S., additional, Forster, K., additional, Kaufeld, T., additional, Kielstein, J., additional, Schilling, T., additional, Haverich, A., additional, Haller, H., additional, Schmidt, B., additional, Hu, P., additional, Liang, X., additional, Chen, Y., additional, LI, R., additional, Jiang, F., additional, LI, Z., additional, Shi, W., additional, Lim, C. C. W., additional, Chia, C. M. L., additional, Tan, A. K., additional, Tan, C. S., additional, Ng, R., additional, Subramani, S., additional, Perez de Jose, A., additional, Bernis Carro, C., additional, Madero Jarabo, R., additional, Bustamante, J., additional, Sanchez Tomero, J. A., additional, Chung, W., additional, Ro, H., additional, Chang, J. H., additional, Lee, H. H., additional, Jung, J. Y., additional, Fazzari, L., additional, Giuliani, A., additional, Scrivano, J., additional, Pettorini, L., additional, Benedetto, U., additional, Luciani, R., additional, Roscitano, A., additional, Napoletano, A., additional, Coclite, D., additional, Cordova, E., additional, Punzo, G., additional, Sinatra, R., additional, Mene, P., additional, Pirozzi, N., additional, Shavit, L., additional, Manilov, R., additional, Algur, N., additional, Wiener-Well, Y., additional, Slotki, I., additional, Pipili, C., additional, Vrettou, C. S., additional, Avrami, K., additional, Economidou, F., additional, Glynos, K., additional, Ioannidou, S., additional, Markaki, V., additional, Douka, E., additional, Nanas, S., additional, De Pascalis, A., additional, Cofano, P., additional, Proia, S., additional, Valletta, A., additional, Vitale, O., additional, Russo, F., additional, Buongiorno, E., additional, Filiopoulos, V., additional, Biblaki, D., additional, Lazarou, D., additional, Chrysis, D., additional, Fatourou, M., additional, Lafoyianni, S., additional, Vlassopoulos, D., additional, Zakiyanov, O., additional, Kriha, V., additional, Vachek, J., additional, Svarcova, J., additional, Zima, T., additional, Tesar, V., additional, Kalousova, M., additional, Kaushik, M., additional, Ronco, C., additional, Cruz, D., additional, Zhang, L., additional, Zhang, W., additional, Chen, N., additional, Ejaz, A. A., additional, Kambhampati, G., additional, Ejaz, N., additional, Dass, B., additional, Lapsia, V., additional, Arif, A. A., additional, Asmar, A., additional, Shimada, M., additional, Alsabbagh, M., additional, Aiyer, R., additional, Johnson, R., additional, Chen, T.-H., additional, Chang, C.-H., additional, Chang, M.-Y., additional, Tian, Y.-C., additional, Hung, C.-C., additional, Fang, J.-T., additional, Yang, C.-W., additional, Chen, Y.-C., additional, Cantaluppi, V., additional, Quercia, A. D., additional, Figliolini, F., additional, Giacalone, S., additional, Pacitti, A., additional, Gai, M., additional, Guarena, C., additional, Leonardi, G., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, De Cal, M., additional, Lentini, P., additional, Clementi, A., additional, Virzi, G. M., additional, Scalzotto, E., additional, Lacquaniti, A., additional, Donato, V., additional, Fazio, M. R., additional, Lucisano, S., additional, Cernaro, V., additional, Lupica, R., additional, Buemi, M., additional, Helvaci, I., additional, Anik, E., additional, Wani, M., additional, Wani, D. I., additional, Bhat, D. M. A., additional, Banday, D. K., additional, Najar, D. M. S., additional, Reshi, D. A. R., additional, Palla, D. N. A., additional, Iglesias, P., additional, Olea, T., additional, Vega-Cabrera, C., additional, Heras, M., additional, Bajo, M. A., additional, Del Peso, G., additional, Arias, M. J., additional, Selgas, R., additional, Diez, J. J., additional, Daher, E., additional, Costa, P. L., additional, Pereira, E. N. S., additional, Santos, R. D. P., additional, Abreu, K. L., additional, Silva Junior, G., additional, Pereira, E. D. B., additional, Raimundo, M., additional, Crichton, S., additional, Syed, Y., additional, Martin, J., additional, Whiteley, C., additional, Bennett, D., additional, Ostermann, M., additional, Gjyzari, A., additional, Thereska, N., additional, Koroshi, A., additional, Barbullushi, M., additional, Kodra, S., additional, Idrizi, A., additional, Strakosha, A., additional, Petrela, E., additional, Lemmich Smith, J., additional, Klimenko, A., additional, Tuykhmenev, E., additional, Villevalde, S., additional, Kobalava, Z., additional, Avdoshina, S., additional, Tyukhmenev, E., additional, Efremovtseva, M., additional, Hayashi, H., additional, Suzuki, S., additional, Kataoka, K., additional, Kondoh, Y., additional, Taniguchi, H., additional, Sugiyama, D., additional, Nishimura, K., additional, Sato, W., additional, Maruyama, S., additional, Matsuo, S., additional, Yuzawa, Y., additional, Geraldine, D., additional, Muriel, F., additional, Alexandre, H., additional, Eric, R., additional, Fu, P., additional, Pozzato, M., additional, Ferrari, F., additional, Cecere, P., additional, Mesiano, P., additional, Vallero, A., additional, Livigni, S., additional, Quarello, F., additional, Hudier, L., additional, Decaux, O., additional, Haddj-Elmrabet, A., additional, Mandart, L., additional, Lino-Daniel, M., additional, Bridoux, F., additional, Renaudineau, E., additional, Sawadogo, T., additional, Le Pogamp, P., additional, Vigneau, C., additional, Famee, D., additional, Koo, H. M., additional, Oh, H. J., additional, Han, S. H., additional, Choi, K. H., additional, Kang, S.-W., additional, Mehdi, M., additional, Nicolas, M., additional, Mariat, C., additional, Shah, P., additional, Kute, V. B., additional, Vanikar, A., additional, Gumber, M., additional, Patel, H., additional, Trivedi, H., additional, Manetos, C., additional, Poulaki, S., additional, Tripodaki, E.-S., additional, Papastylianou, A., additional, Routsi, C., additional, Uchida, K., additional, Kensuke, U., additional, Yamagata, K., additional, Saitou, C., additional, Okada, M., additional, Chita, G., additional, Davies, M., additional, Veriawa, Y., additional, Naicker, S., additional, Mukhopadhyay, P., additional, Mukherjee, D., additional, Mishra, R., additional, Kar, M., additional, Zickler, D., additional, Wesselmann, H., additional, Schindler, R., additional, Gutierrez*, E., additional, Egido, J., additional, Rubio-Navarro, A., additional, Buendia, I., additional, Blanco-Colio, L. M., additional, Toldos, O., additional, Manzarbeitia, F., additional, De Lorenzo, A., additional, Sanchez, R., additional, Praga^, M., additional, Moreno^, J. A., additional, Kim, M. Y., additional, Kang, N. R., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, Y.-G., additional, Kim, D. J., additional, Hong, S.-C., additional, Kim, J.-S., additional, Oh, H. Y., additional, Okamoto, T., additional, Kamata, K., additional, Naito, S., additional, Tazaki, H., additional, Kan, S., additional, Anne-Kathrin, L.-G., additional, Matthias, K., additional, Speer, T., additional, Andreas, L., additional, Heinrich, G., additional, Thomas, V., additional, Poppleton, A., additional, Danilo, F., additional, Lai, C.-F., additional, Wu, V.-C., additional, Shiao, C.-C., additional, Huang, T.-M., additional, Wu, K.-D., additional, Bedford, M., additional, Farmer, C., additional, Irving, J., additional, Stevens, P., additional, Patera, F., additional, Mattozzi, F., additional, Battistoni, S., additional, Fagugli, R. M., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Xie, H., additional, Chen, H., additional, Xu, S., additional, He, Q., additional, Liu, J., additional, Hu, W., additional, Liu, Z., additional, Dalboni, M., additional, Blaya, R., additional, Quinto, B. M., additional, Narciso, R., additional, Oliveira, M., additional, Monte, J., additional, Durao, M., additional, Cendoroglo, M., additional, Batista, M., additional, Hanemann, A. L., additional, Liborio, A., additional, Martins, A., additional, Pinheiro, M. C. C., additional, Meneses, G., additional, De Paula Pessoa, R., additional, Sousa, M., additional, Bezerra, F. S. M., additional, Albuquerque, P. L. M. M., additional, Lima, J. B., additional, Lima, C. B., additional, Veras, M. D. S. B., additional, Nemoto Matsui, T., additional, Totoli, C., additional, Cruz Andreoli, M. C., additional, Vilela Coelho, M. P., additional, Guimaraes de Souza, N. K., additional, Ammirati, A. L., additional, De Carvalho Barreto, F., additional, Ferraz Neto, B.-H., additional, Fortunato Cardoso Dos Santos, B., additional, Abraham, A., additional, Abraham, G., additional, Mathew, M., additional, Duarte, P. M. A., additional, Duarte, F. B., additional, Barros, E. M., additional, Castro, F. Q. S., additional, Palomba, H., additional, Castro, I., additional, Sousa, S. R., additional, Jesus, A. N., additional, Romano, T., additional, Burdmann, E., additional, Yu, L., additional, Kwon, S. H., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Jeon, J. S., additional, Noh, H. J., additional, Han, D. C., additional, Tozija, L., additional, Petronievic, Z., additional, Selim, G., additional, Nikolov, I., additional, Stojceva-Taneva, O., additional, Cakalaroski, K., additional, Lukasz, A., additional, Beneke, J., additional, Menne, J., additional, Schiffer, M., additional, Polanco, N., additional, Hernandez, E., additional, Gutierrez, E., additional, Gutierrez Millet, V., additional, Gonzalez Monte, E., additional, Morales, E., additional, Praga, M., additional, Francisco Javier, L., additional, Nuria, G.-F., additional, Jose Maria, M.-G., additional, Bes Rastrollo, M., additional, Angioi, A., additional, Conti, M., additional, Cao, R., additional, Atzeni, A., additional, Pili, G., additional, Matta, V., additional, Murgia, E., additional, Melis, P., additional, Binda, V., additional, Pani, A., additional, Thome*, F., additional, Leusin, F., additional, Barros, E., additional, Morsch, C., additional, Balbinotto, A., additional, Pilla, C., additional, Premru, V., additional, Buturovic-Ponikvar, J., additional, Ponikvar, R., additional, Marn-Pernat, A., additional, Knap, B., additional, Kovac, J., additional, Gubensek, J., additional, Kersnic, B., additional, Krnjak, L., additional, Prezelj, M., additional, Granatova, J., additional, Havrda, M., additional, Hruskova, Z., additional, Kratka, K., additional, Remes, O., additional, Mokrejsova, M., additional, Bolkova, M., additional, Lanska, V., additional, Rychlik, I., additional, Uniacke, M. D., additional, Lewis, R. J., additional, Harris, S., additional, Roderick, P., additional, Martin, N., additional, Ulrich, K., additional, Jan, B., additional, Jorn, B., additional, Reinhard, B., additional, Jan, K., additional, Hermann, H., additional, Meyer Tobias, F., additional, Leyla, R., additional, Schmidt Bernhard, M. W., additional, Harald, S., additional, Jurgen, S., additional, Tanja, K., additional, Mario, S., additional, Sang Hi, E., additional, Claus, M., additional, Frank, V., additional, Aleksej, S., additional, Sengul, S., additional, Robert, S., additional, Karin, W., additional, Feikah, G., additional, Menne Tobias, F., additional, Meyer Tobias, N., additional, Beutel, G., additional, Fleig, S., additional, Steinhoff, J., additional, Meyer, T., additional, Hafer, C., additional, Bramstedt, J., additional, Busch, V., additional, Vischedyk, M., additional, Kuhlmann, U., additional, Ries, W., additional, Mitzner, S., additional, Mees, S., additional, Stracke, S., additional, Nurnberger, J., additional, Gerke, P., additional, Wiesner, M., additional, Sucke, B., additional, Abu-Tair, M., additional, Kribben, A., additional, Klause, N., additional, Merkel, F., additional, Schnatter, S., additional, Dorresteijn, E., additional, Samuelsson, O., additional, Brunkhorst, R., additional, Stec-Hus Registry, G., additional, Reising, A., additional, Bange, F.-C., additional, Hiss, M., additional, Vetter, F., additional, Bode-Boger, S. M., additional, Martens-Lobenhoffer, J., additional, Schmidt, B. M. W., additional, Kielstein, J. T., additional, Shin, H. S., additional, Jung, Y. S., additional, and Rim, H., additional
Published: 2012
Full Text: View/download PDF

20. Use of Elderly Living Kidney Donors: Twenty Years' Experience in the Balkans

Author: Ivanovski, N., primary, Masin, J., additional, Kolevski, P., additional, Stojceva-Taneva, O., additional, and Popov, Z., additional
Published: 2011
Full Text: View/download PDF

21. Brain Natriuretic Peptide between Traditional and Nontraditional Risk Factors in Hemodialysis Patients: Analysis of Cardiovascular Mortality in a Two-Year Follow-Up

Author: Selim, G., primary, Stojceva-Taneva, O., additional, Spasovski, G., additional, Georgievska-Ismail, L., additional, Zafirovska-Ivanovska, B., additional, Gelev, S., additional, Dzekova, P., additional, Trajcevska, L., additional, Trojacanec-Piponska, S., additional, and Sikole, A., additional
Published: 2011
Full Text: View/download PDF

22. Cardiovascular complications in CKD 5D (1)

Author: Kuo, K.-L., primary, Hung, S.-C., additional, Tarng, D.-C., additional, Selim, G., additional, Stojceva-Taneva, O., additional, Tozija, L., additional, Gelev, S., additional, Stojcev, N., additional, Dzekova, P., additional, Trajcevska, L., additional, Severova, G., additional, Pavleska, S., additional, Sikole, A., additional, Combe, C., additional, Thumma, J., additional, Gillespie, B., additional, De Sequera, P., additional, Yamamoto, H., additional, Robinson, B., additional, Matsushita, Y., additional, Tasaki, H., additional, Tohara, Y., additional, Yamauchi, E., additional, Matsuoka, K., additional, Arizono, K., additional, Bellasi, A., additional, Ferramosca, E., additional, Ratti, C., additional, Block, G., additional, Raggi, P., additional, Drozdz, M., additional, Krasniak, A., additional, Chmiel, G., additional, Podolec, P., additional, Pasowicz, M., additional, Tracz, W., additional, Kowalczyk-Michalek, M., additional, Sulowicz, W., additional, Kalantzi, K., additional, Korantzopoulos, P., additional, Bechlioulis, A., additional, Vlachopanou, A., additional, Foulidis, V., additional, Pagiati, E., additional, Nikolopoulos, P., additional, Gouva, C., additional, Arroyave, I., additional, Rodelo, J., additional, Cardona, M., additional, Garcia, A., additional, Henao, J., additional, Mejia, G., additional, Rico, J., additional, Arbelaez, M., additional, Fujimori, A., additional, Okada, S., additional, Yamamoto, K., additional, Okamoto, S., additional, Kamiura, N., additional, Sakai, M., additional, Tanikake, M., additional, Kutlay, S., additional, Sengul, S., additional, Keven, K., additional, Nergizoglu, G., additional, Erturk, S., additional, Ates, K., additional, Duman, N., additional, Karatan, O., additional, Erbay, B., additional, Sameiro-Faria, M., additional, Costa, E., additional, Rocha-Pereira, P., additional, Borges, A., additional, Nascimento, H., additional, Mendonca, D., additional, Amado, L., additional, Reis, F., additional, Miranda, V., additional, Quintanilha, A., additional, Belo, L., additional, Santos-Silva, A., additional, Oh, J. S., additional, Kim, S. M., additional, Sin, Y. H., additional, Kim, J. K., additional, Ishihara, M., additional, Otsubo, S., additional, Kimata, N., additional, Akiba, T., additional, Nitta, K., additional, Kim, K. M., additional, Baek, C. H., additional, Kim, S. B., additional, Testa, A., additional, Sanguedolce, M. C., additional, Spoto, B., additional, Mallamaci, F., additional, Malatino, L., additional, Tripepi, G., additional, Zoccali, C., additional, Lee, J. E., additional, Moon, S. J., additional, Kim, J.-K., additional, An, H. R., additional, Ha, S. K., additional, Pakr, H. C., additional, Bahlmann, F. H., additional, Becker, E., additional, Sperber, V., additional, Triem, S., additional, Noll, C., additional, Zewinger, S., additional, Fliser, D., additional, Laufs, U., additional, Thijssen, S., additional, Usvyat, L. A., additional, Raimann, J. G., additional, Balter, P., additional, Kotanko, P., additional, Levin, N. W., additional, Hornum, M., additional, Bay, J. T., additional, Clausen, P., additional, Melchior Hansen, J., additional, Mathiesen, E. R., additional, Feldt-Rasmussen, B., additional, Garred, P., additional, Sural, S., additional, Panja, C. S., additional, Bhattacharya, S. K., additional, Cernaro, V., additional, Lacquaniti, A., additional, Lorenzano, G., additional, Romeo, A., additional, Donato, V., additional, Buemi, M., additional, Usvyat, L., additional, Rogus, J., additional, Lacson, E., additional, Robinson, B. M., additional, Karaboyas, A., additional, Sen, A., additional, Hecking, M., additional, Mendelssohn, D., additional, Jadoul, M., additional, Kawanishi, H., additional, Saran, R., additional, Kolarz, M., additional, Undas, A., additional, Wyroslak, J., additional, Malyszko, J., additional, Klejna, K., additional, Naumnik, B., additional, Koc-Zurawska, E., additional, Mysliwiec, M., additional, Piecha, G., additional, Kuczera, P., additional, Adamczak, M., additional, Fedorova, O. V., additional, Bagrov, A. Y., additional, Wiecek, A., additional, Gungor, O., additional, Kircelli, F., additional, Asci, G., additional, Carrero, J. J., additional, Tatar, E., additional, Demirci, M., additional, Toz, H., additional, Ozkahya, M., additional, Ok, E., additional, Bansal, V., additional, Shareain, K., additional, Hoppensteadt, D., additional, Litinas, E., additional, Fareed, J., additional, Kim, M.-J., additional, Lee, S. W., additional, Song, J. H., additional, Kweon, J., additional, Kim, W. H., additional, Sasaki, K., additional, Yasuda, K., additional, Hatanaka, M., additional, Hayashi, T., additional, Katsipi, I., additional, Tatsiopoulos, A., additional, Papanikolaou, P., additional, Doulgerakis, C., additional, Kollia, K., additional, Kardouli, E., additional, Asmanis, E., additional, Gennadiou, M., additional, Kyriazis, J., additional, Panizo, S., additional, Barrio-Vazquez, S., additional, Carrillo-Lopez, N., additional, Fernandez-Vazquez, A., additional, Braga, S., additional, Rodriguez-Rebollar, A., additional, Naves-Diaz, M., additional, Cannata-Andia, J. B., additional, Nikodimopoulou, M., additional, Liakos, S., additional, and Kapoulas, S., additional
Published: 2011
Full Text: View/download PDF

23. Tubular markers in diabetes in relation to microangiopathy

Author: Stojceva-Taneva, O., primary, Ivanovski, N., additional, Grozdanovski, R., additional, Gruev, T., additional, and Polenakovic, M., additional
Published: 1996
Full Text: View/download PDF

24. ASSOCIATION BETWEEN HAEMOGLOBIN LEVEL AND ALL-CAUSE MORTALITY IN HAEMODIALYSIS PATIENTS: THE LINK WITH INFLAMMATION AND MALNUTRITION.

Author: Selim, G., Stojceva-Taneva, O., Sikole, A., Amitov, V., Trajcevska, L., Asani, A., Trojacanec-Piponska, S., and Polenakovic, M.
Subjects: *HEMODIALYSIS patients, *ANEMIA, *HEMOGLOBINS, *MALNUTRITION, *INFLAMMATION
Abstract: Although anaemia management has improved in haemodialysis (HD) patients in recent years, many of them still have haemoglobin (Hb) levels below the current recommendations. The consequent anaemia could be one of the links between malnutrition and inflammation, and higher mortality in HD patients. The study objective was to determine the relationship between Hb levels and outcome in patients undergoing HD, accounting for inflammation and malnutrition. We retrospectively analysed a total of 236 patients on HD between January 2003 and December 2005, classified by absence or presence of inflammation and malnutrition (defined as serum albumin levels < 40 g/L and CRP > 8mg/1). Serum levels of Hb, ferritin, creatinine, cholesterol, triglycerides, HDL (high-density lipoprotein cholesterol), LDL (low-density lipoprotein cholesterol), albumin and CRP were measured monthly, fibrinogen was measured every third month. Over the period of three years, 73 out of 236 patients (30%) had died, most from cardiovascular diseases (62%). Presence of inflammation and malnutrition (in 44% of patients) was associated with older age (60.69 ± 12.46 vs. 54.52 ± 12.37, p = 0.0002), lower levels of Hb (99.53 ± 14.97 vs. 111.86 ± 10.38 g/l, p = 0.0000), creatinine (835.88 ± 179.84 vs. 1069.98 ± 821.23 µmol/1, p = 0.0047), albumin (36.58 ± 3.41 vs. 40.32 ± 2.82 g/l, p = 0.0000), cholesterol (4.32 ± 1.04 vs. 4.75 ± 1.09 mmol/1, p = 0.0025) and higher levels of fibrinogen (4.94 ± 1.18 vs. 4.29 ± 0.91g/1, p = 0.0000) and CRP (30.42 ± 29.47 vs. 5.24 ± 4.89 mg/1, p = 0.0000). The Kaplan-Meier analysis showed that, irrespective of the absence or presence of inflammation and malnutrition, the all-cause mortality was higher in patients with Hb < 110 g/1 (Log-Rank, p = 0.00147; p = 0.00222). On the other hand, Kaplan-Meier showed that, irrespective of the absence or presence of anaemia (Hb > 110 g/l and Hb < 110 g/l), the all-cause mortality was higher in patients with the presence of inflammation and malnutrition (Log-Rank, p = 0.00222; p = 0.00263). The Cox proportional hazard analysis, adjusting for age, showed that only lower serum levels of Hb and higher CRP were associated with all-cause mortality (chi-square = 110,306, p = 0.0000). Our findings confirm the association of lib levels < 110 g/L with higher mortality among maintenance HD patients, especially in patients with the presence of inflammation and malnutrition. Further investigation of the relationships among anaemia, inflammation and malnutrition and survival is warranted. [ABSTRACT FROM AUTHOR]
Published: 2007

25. Elevated basal levels of cytosolic calcium of thymocytes in chronic renal failure.

Author: Stojceva-Taneva, Olivera, Smogorzewski, Miroslaw, Fadda, George Z., Massry, Shaul G., Stojceva-Taneva, O, Smogorzewski, M, Fadda, G Z, and Massry, S G
Published: 1993
Full Text: View/download PDF

26. Verapamil reverses glucose intolerance in preexisting chronic renal failure: studies on mechanisms.

Author: Thanakitcharu, Prasert, Fadda, George Z., Hajjar, Suha M., Levi, Edi, Stojceva-Taneva, Olivera, Massry, Shaul G., Thanakitcharu, P, Fadda, G Z, Hajjar, S M, Levi, E, Stojceva-Taneva, O, and Massry, S G
Published: 1992
Full Text: View/download PDF

27. Autonomic nervous system dysfunction and volume nonresponsive hypotension in hemodialysis patients.

Author: Stojceva-Taneva, Olivera, Masin, Giorgi, Polenakovic, Momir, Stojcev, Saso, Stojkovski, Ljupco, Stojceva-Taneva, O, Masin, G, Polenakovic, M, Stojcev, S, and Stojkovski, L
Published: 1991
Full Text: View/download PDF

28. Vascular access in hemodialyis patients - registry data.

Author: Stojceva-Taneva, O and Selim, G
Subjects: *HEMODIALYSIS, *ARTERIAL catheterization, *MEDICAL care, *MEDICAL records, *PATIENT education
Abstract: Background: The use of arteriovenous fistula over a central venous catheter in hemodialysis patients is recommended whenever possible. It has become the gold standard among all the available permanent vascular accesses for hemodialysis as it is associated with less complications. The aim of our study was to analyze the type of vascular access in hemodialysis patients in our country, FYR of Macedonia and to see its association with other variables recorded by the National Renal Registry in 2009. Material and methods: Data were collected by 18 hemodialysis centers in the country. A total of 1,457 patients were analyzed. One hundred and ninety one patients were incident, and 164 out of 1,457 died during the year. Except for 9 patients, all the others had data on type of vascular access, as well as data on any vascular access intervention performed during the year. Results: The overall mean age was 58.8 ± 13.1 years. Eighty-nine percent of the non-incident patients (prevalent plus those who died during the year) had arteriovenous fistula, 10.6% central venous catheter and 0.2% vascular graft. When incident to non-incident patients were compared, incident patients were significantly older, had significantly higher mortality and significantly lower percentage of arteriovenous fistula. Patients with arteriovenous fistula had significantly longer dialysis vintage and significantly less deaths compared to those with central venous catheters. Conclusions: The study showed that the number of non-incident hemodialysis patients with arteriovenous fistula in the country was high. The incident hemodialysis patients have high number of central venous catheters as vascular access for hemodialysis and significantly higher mortality compared to non-incident patients. Hippokratia 2014; 18 (3): 209-211. [ABSTRACT FROM AUTHOR]
Published: 2014

29. Dialysis in Adults in Year 2000 in the Republic of Macedonia

Author: Polenakovic, M.H., Sikole, A., Grozdanovski, R., Amitov, V., Stojkovski, Lj., Oncevski, A., Grcevska, L., Dzikova, S., Cakalaroski, K., Bogdanovska, S., Gerasimovska, V., Gerasimovska, B., Milovanceva, M., Stojceva-Taneva, O., Krstanovski, B., Kovaceski, S., Serijat, M., Mustafa, Z., Capova, O., Bajalska, A., Nikolovski, A., Filipovic, R., Neskovski, J., Selja, Lj., Janakievska, P., Lamova, K., Hristova, V., Sarajlija, E. Karceva, Romeo, M., Mitrevski, Z., Ivanovski, K., Dimitrov, S., Velinova, B., and Panova, B.
Abstract: 1,019 adult patients with terminal renal failure were treated with dialysis (D) in the first part of the year 2000 in the Republic of Macedonia. 1,010 patients (99%) were treated with chronic intermittent (maintenance) hemodialysis (HD) while nine patients (1%) were on continuous ambulatory peritoneal dialysis (CAPD). For the children, a special peritoneal dialysis program was developed; 509 patients per million of the population (PMP) were on dialysis.The Republic of Macedonia is, therefore, among those central and eastern European countries with a higher PMP number in the treatment of end-stage renal disease, following Croatia, the Czech Republic and Slovenia.The patients were treated at 18 Centers in a network of HD Centers at a distance of 30–50 km. from their place of residence in order to facilitate their access to treatment and to work. All patients who have had symptoms indicating need for treatment with D were accepted for treatment. The government payed all the expenses of the treatment and the salaries of the staff. 56% were male and 44% were female patients. The youngest patient was aged 9 and the oldest was 82 years old. There has been an increase in the age of the patients on D as well as an increase in their number. In 1993 we had 727 patients being treated with D, and now we have 1,019 with a constant increase in the number of patients with ESRD and a need for D and renal transplantation. Mortality per year at the different Centers ranged from 8–19% in 1999 and the average is 12%.Glomerulonephritis (GN) – both primary and secondary – is the main cause of renal failure (RF) in some Centers up to 45%. Tubulo-interstitial disease follows GN. ADPKD patients constitute 9.4% with a difference among the Centers of 3–29%, and diabetic nephropathy is found in 10%, 5–15% in different Centers. 11–61% of patients have an unknown etiology.352 patients are on treatment with human recombinant erythropoietin (rhuEPO) – in some Centers up to 60%. The mode of application was subcutaneous and the initial dose is 20 U/kg body weight and the mean maintenance dose of EPO per patient weekly is 4,000 U.The Cimino-Brescia arteriovenous fistula is being applied as a standard vascular access. The survival rate of our patients treated with maintenance HD at 5 years was 58%. CAPD and particularly renal transplantation are to be further developed as alternative methods in treating terminal renal failure.
Published: 2002
Full Text: View/download PDF

30. Effects of glucocorticoid immunosuppression on serum cystatin C levels

Author: Gruev Todor, Chakalarovski Koco, Stojceva-Taneva Olivera, Grueva Ani, and Trenceva Katerina
Subjects: cystatin c, renal transplantation, methylprednisolone, Biochemistry, QD415-436
Abstract: The aim of the present study is to describe the influence of glucocorticoid immunosuppression on serum cystatin C concentration in renal transplant patients. To evaluate the influence of immunosuppressive regimens, espe- cially glucocorticoids, on serum cystatin C level, 38 clinically stable patients on immunosuppression therapy with low-dose glucocorticoids were compared to 30 clinically stable patients receiving cyclosporin A alone, and 18 clinically stable patients receiving cyclosporin A together with azathioprine. Clinical stability was defined as the absence of acute rejection, febrile infection, and cyclosporin A toxicity, as well as stability of creatinine clearance as estimated by the formula of Cockroft and Gault. All groups were compared for estimated creatinine clearance (CrCl) values and had comparable gender, age and time since transplantation. The group receiving short-course, high-dose methylprednisolone was analyzed at four time points: a) before methylprednisolone commencement (median, 15 days); b) the day methylprednisolone was introduced (before medication); c) after 3 days of methylprednisolone therapy; and d) on a follow-up 9-10 days after the last dose. Intravenous administration of high-dose methylprednisolone led to significant differences in cystatin C levels at different time points (before administration, after three doses, and 8 days after discontinuation). Glucocorticoid medication in adult renal transplant patients is associated in a dose-dependent manner with increased cystatin C, leading to systematic under estimation of GFR. Moreover, our data illustrate the need for specific reference intervals in patients on glucocorticoid therapy. In clinical routine settings, as well as in future clinical studies, it is important to take glucocorticoid medication into account when interpreting serum cystatin C concentrations in renal transplant patients presumably, as well as in other patient groups.
Published: 2009

31. Correlation between published methods to predict creatinine clearance and measured creatinine clearance in diabetic nephropathy elderly patients

Author: Mladenovska, K., Katerina Goracinova, Stojceva-Taneva, O., and Stojkovski, Lj

32. Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients

Author: Olivera Stojceva-Taneva, Andrew Smith, Katerina Markoska, Fulvio Magni, Lotte Jacobs, Martin Pejchinovski, Harald Mischak, Claudia Pontillo, Goce Spasovski, Momir Polenakovic, Jelka Masin-Spasovska, Petra Zürbig, Markoska, K, Pejchinovski, M, Pontillo, C, Zurbig, P, Jacobs, L, Smith, A, Masin-Spasovska, J, Stojceva-Taneva, O, Polenakovic, M, Magni, F, Mischak, H, and Spasovski, G
Subjects: 0301 basic medicine, Male, medicine.medical_specialty, Proteome, Urinary system, Urology, Renal function, Urine, Kidney, Cohort Studies, 03 medical and health sciences, Medicine, Humans, Biomarker discovery, Renal Insufficiency, Chronic, Peptide sequence, biomarkers, CKD, diagnosis, GFR, urine peptide markers, Transplantation, business.industry, Area under the curve, Middle Aged, medicine.disease, Peptide Fragments, 030104 developmental biology, ROC Curve, Nephrology, Cohort, Disease Progression, Female, business, Biomarkers, Kidney disease, Glomerular Filtration Rate
Abstract: Background An improvement in the glomerular filtration rate (GFR) of chronic kidney disease patients has been an underestimated clinical outcome. Although this may be considered as an unexpected disease course, it may provide some insights into possible mechanisms underlying disease remission and/or regression. Therefore, our aim was to identify urinary peptide biomarkers associated with an improvement in estimated GFR (eGFR) over time and to improve patient stratification. Methods Capillary electrophoresis coupled with mass spectrometry (CE-MS) was employed to evaluate the urine peptidome of patients with different types of renal diseases. In total, 376 patients with a slope/year between -1.5% and +1.5% were designated as non-progressors or stable, while 177 patients with a > 5% slope/year were designated as patients with an improved eGFR for state-of-art biomarker discovery and validation. Results We detected 384 significant peptide fragments by comparing the CE-MS data of the stable patients and those with improved renal function in our development cohort. Of these 384, a set of 141 peptides with available amino acid sequence information were used to generate a support vector machine-based classification panel. The biomarker panel was applied to our validation cohort, achieving a moderate area under the curve (AUC) value of 0.85 (81% sensitivity and 81% specificity). The majority of the peptides (78%) from the diagnostic panel arose from different types of collagen. Conclusions We have developed a panel of urinary peptide markers able to discriminate those patients predisposed to improve their kidney function over time and possibly be treated with more specific or less aggressive therapy.
Published: 2017

33. Effects of Standard and Individualized Dialysate Sodium in Chronic Hemodialysis Patients Upon Echocardiography Parameters.

Author: Eftimovska-Otovikj N, Stojceva-Taneva O, and Petkovikj N
Subjects: Blood Pressure, Echocardiography, Humans, Renal Dialysis adverse effects, Renal Dialysis methods, Sodium analysis, Sodium pharmacology, Weight Gain, Dialysis Solutions adverse effects, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy
Abstract: Aims : This study assessed the effects of individualized dialysis sodium prescription on changes of echo-cardiography in hemodialysis (HD) patients. Methods : 77 chronic hemodialysis patients were analysed. In the first phase all patients underwent dialysis with standard dialysate sodium of 138 mmol/L followed by the second phase where dialysis was performed with individualized dialysate sodium concentration according to average pre HD serum sodium concentration. After the first phase, the subjects were divided into 3 groups: normotensive, hypertensive and hypotensive based on the average pre-HD systolic BP during the first phase. In all patients echocardiography was performed at the end of the first and second phase. Results : Patients had no statistical significant change in blood pressure compared with standard dialysate sodium, only statistical significant change in interdialytic weight gain (IDWG). By dividing the patients, sodium individualization resulted in significantly lower blood pressure and IDWG (p=0.018) in hyper-tensive patients, whereas normotensive patients showed only significant decrease in IDWG (p=0,004). Hypertensive patients had significant highest sodium gradient compared to other patients (p<0.05), followed by significant increase of 0,6% IDWG confirmed with univariate regression analysis. In all patients, echocardiography analysis showed an increase of 2.04 mm of LVDD by increasing the sodium gradient for 1 mmol/L and significantly increased LVM of 35.69 gr by 1 kg increase in IDWG. Conclusions : A reduction of the dialysate sodium concentration based on the pre HD serum sodium level of the patient, reduced the SBP, DBP and IDWG and decreased the volume overload upon the heart and consequently heart hypertrophy assessed by echocardiography., (© 2022 Natasha Eftimovska-Otovikj et al., published by Sciendo.)
Published: 2022
Full Text: View/download PDF

34. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe.

Author: Stel VS, de Jong RW, Kramer A, Andrusev AM, Baltar JM, Barbullushi M, Bell S, Castro de la Nuez P, Cernevskis H, Couchoud C, De Meester J, Eriksen BO, Gârneaţă L, Golan E, Helve J, Hemmelder MH, Hommel K, Ioannou K, Jarraya F, Kantaria N, Kerschbaum J, Komissarov KS, Magaz Á, Mercadal L, Ots-Rosenberg M, Pálsson R, Rahmel A, Rydell H, Savino M, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, van der Tol A, Vazelov ES, Ziginskiene E, Zurriaga Ó, Vanholder RC, Massy ZA, and Jager KJ
Subjects: Conservative Treatment, Edetic Acid, Europe, Germany, Greece, Humans, Ireland, Italy, Portugal, Registries, Renal Dialysis adverse effects, Spain, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic therapy, Kidney Transplantation adverse effects, Renal Insufficiency
Abstract: The aims of this study were to determine the frequency of dialysis and kidney transplantation and to estimate the regularity of comprehensive conservative management (CCM) for patients with kidney failure in Europe. This study uses data from the ERA-EDTA Registry. Additionally, our study included supplemental data from Armenia, Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova, Montenegro, Slovenia and additional data from Israel, Italy, Slovakia using other information sources. Through an online survey, responding nephrologists estimated the frequency of CCM (i.e. planned holistic care instead of kidney replacement therapy) in 33 countries. In 2016, the overall incidence of replacement therapy for kidney failure was 132 per million population (pmp), varying from 29 (Ukraine) to 251 pmp (Greece). On 31 December 2016, the overall prevalence of kidney replacement therapy was 985 pmp, ranging from 188 (Ukraine) to 1906 pmp (Portugal). The prevalence of peritoneal dialysis (114 pmp) and home hemodialysis (28 pmp) was highest in Cyprus and Denmark respectively. The kidney transplantation rate was nearly zero in some countries and highest in Spain (64 pmp). In 28 countries with five or more responding nephrologists, the median percentage of candidates for kidney replacement therapy who were offered CCM in 2018 varied between none (Slovakia and Slovenia) and 20% (Finland) whereas the median prevalence of CCM varied between none (Slovenia) and 15% (Hungary). Thus, the substantial differences across Europe in the frequency of kidney replacement therapy and CCM indicate the need for improvement in access to various treatment options for patients with kidney failure., (Copyright © 2021 International Society of Nephrology. All rights reserved.)
Published: 2021
Full Text: View/download PDF

35. The ERA-EDTA Registry Annual Report 2017: a summary.

Author: Kramer A, Boenink R, Noordzij M, Bosdriesz JR, Stel VS, Beltrán P, Ruiz JC, Seyahi N, Comas Farnés J, Stendahl M, Garneata L, Winzeler R, Golan E, Lopot F, Korejwo G, Bonthuis M, Lassalle M, Slon Roblero MF, Kuzema V, Hommel K, Stojceva-Taneva O, Asberg A, Kramar R, Hemmelder MH, De Meester J, Vazelov E, Andrusev A, Castro de la Nuez P, Helve J, Komissarov K, Casula A, Magaz Á, Santiuste de Pablos C, Bubić I, Traynor JP, Ioannou K, Idrizi A, Palsson R, des Grottes JM, Spustova V, Tolaj-Avdiu M, Jarraya F, Nordio M, Ziginskiene E, Massy ZA, and Jager KJ
Abstract: Background: This article presents a summary of the 2017 Annual Report of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 37 countries., Methods: The ERA-EDTA Registry received individual patient data on patients undergoing RRT for ESRD in 2017 from 32 national or regional renal registries and aggregated data from 21 registries. The incidence and prevalence of RRT, kidney transplantation activity and survival probabilities of these patients were calculated., Results: In 2017, the ERA-EDTA Registry covered a general population of 694 million people. The incidence of RRT for ESRD was 127 per million population (pmp), ranging from 37 pmp in Ukraine to 252 pmp in Greece. A total of 62% of patients were men, 52% were ≥65 years of age and 23% had diabetes mellitus as the primary renal disease. The treatment modality at the onset of RRT was haemodialysis for 85% of patients. On 31 December 2017, the prevalence of RRT was 854 pmp, ranging from 210 pmp in Ukraine to 1965 pmp in Portugal. The transplant rate in 2017 was 33 pmp, ranging from 3 pmp in Ukraine to 103 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2008-12, the unadjusted 5-year patient survival probability for all RRT modalities combined was 50.8%., (© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.)
Published: 2020
Full Text: View/download PDF

36. Uric acid and left ventricular hypertrophy: another relationship in hemodialysis patients.

Author: Selim G, Stojceva-Taneva O, Tozija L, Zafirova-Ivanovska B, Spasovski G, Gerasimovska V, Petronijevic Z, Trajceska L, Dzekova-Vidimliski P, Gjorgjievski N, Pavleska-Kuzmanovska S, Kabova A, and Georgievska-Ismail L
Abstract: Background: The impact of serum uric acid (UA) on morbidity and mortality in hemodialysis (HD) patients is quite controversial in relation to the general population. The aim of this study was to evaluate the association of serum UA with both mortality and left ventricular hypertrophy (LVH) in HD patients., Methods: This longitudinal study enrolled 225 prevalent HD patients who were classified into three groups according to their follow-up-averaged UA (FA-UA) levels: low FA-UA (FA-UA <400 µmol/L), intermediate/reference FA-UA (FA-UA between 400 and 450 µmol/L) and high FA-UA (FA-UA >450 µmol/L). Echocardiography was performed on a nondialysis day and the presence of LVH was defined based on a left ventricular mass index (LVMI) >131 and >100 g/m 2 for men and women, respectively. The patients were followed during a 60-month period., Results: The mean FA-UA level was 425 ± 59 µmol/L (range 294-620). There was a consistent association of higher FA-UA with better nutritional status (higher body mass index, normalized protein catabolic rate, creatinine, albumin and phosphorus), higher hemoglobin, but lower C-reactive protein and LVMI. During the 5-year follow-up, 81 patients died (36%) and the main causes of death were cardiovascular (CV) related (70%). When compared with the reference group, the hazard ratio for all-cause mortality was 1.75 [95% confidence interval (CI) 1.02-2.98; P = 0.041] in the low FA-UA group, but there was no significant association with the high FA-UA group. In contrast, FA-UA did not show an association with CV mortality neither with the lower nor with the high FA-UA group. The unadjusted odds ratio (OR) of LVH risk in the low FA-UA compared with the reference FA-UA group was 3.11 (95% CI 1.38-7.05; P = 0.006), and after adjustment for age, gender, diabetes and CV disease, ORs for LVH persisted significantly only in the low FA-UA group [OR 2.82 (95% CI 1.16-6.88,); P = 0.002]., Conclusions: Low serum UA is a mortality risk factor and is associated with LVH in HD patients. These results are in contrast with the association of UA in the general population and should be the subject of further research., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.)
Published: 2019
Full Text: View/download PDF

37. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary.

Author: Kramer A, Pippias M, Noordzij M, Stel VS, Andrusev AM, Aparicio-Madre MI, Arribas Monzón FE, Åsberg A, Barbullushi M, Beltrán P, Bonthuis M, Caskey FJ, Castro de la Nuez P, Cernevskis H, De Meester J, Finne P, Golan E, Heaf JG, Hemmelder MH, Ioannou K, Kantaria N, Komissarov K, Korejwo G, Kramar R, Lassalle M, Lopot F, Macário F, Mackinnon B, Pálsson R, Pechter Ü, Piñera VC, Santiuste de Pablos C, Segarra-Medrano A, Seyahi N, Slon Roblero MF, Stojceva-Taneva O, Vazelov E, Winzeler R, Ziginskiene E, Massy Z, and Jager KJ
Abstract: Background: This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries., Methods: In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined., Results: In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007-11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007-11, the adjusted patient survival probabilities appeared to be higher for women than for men., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.)
Published: 2019
Full Text: View/download PDF

38. Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients.

Author: Markoska K, Pejchinovski M, Pontillo C, Zürbig P, Jacobs L, Smith A, Masin-Spasovska J, Stojceva-Taneva O, Polenakovic M, Magni F, Mischak H, and Spasovski G
Subjects: Cohort Studies, Disease Progression, Female, Humans, Male, Middle Aged, ROC Curve, Biomarkers urine, Glomerular Filtration Rate, Kidney physiopathology, Peptide Fragments urine, Proteome analysis, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic urine
Abstract: Background: An improvement in the glomerular filtration rate (GFR) of chronic kidney disease patients has been an underestimated clinical outcome. Although this may be considered as an unexpected disease course, it may provide some insights into possible mechanisms underlying disease remission and/or regression. Therefore, our aim was to identify urinary peptide biomarkers associated with an improvement in estimated GFR (eGFR) over time and to improve patient stratification., Methods: Capillary electrophoresis coupled with mass spectrometry (CE-MS) was employed to evaluate the urine peptidome of patients with different types of renal diseases. In total, 376 patients with a slope/year between -1.5% and +1.5% were designated as non-progressors or stable, while 177 patients with a > 5% slope/year were designated as patients with an improved eGFR for state-of-art biomarker discovery and validation., Results: We detected 384 significant peptide fragments by comparing the CE-MS data of the stable patients and those with improved renal function in our development cohort. Of these 384, a set of 141 peptides with available amino acid sequence information were used to generate a support vector machine-based classification panel. The biomarker panel was applied to our validation cohort, achieving a moderate area under the curve (AUC) value of 0.85 (81% sensitivity and 81% specificity). The majority of the peptides (78%) from the diagnostic panel arose from different types of collagen., Conclusions: We have developed a panel of urinary peptide markers able to discriminate those patients predisposed to improve their kidney function over time and possibly be treated with more specific or less aggressive therapy.
Published: 2018
Full Text: View/download PDF

39. The Spectrum of Histopathological Changes in the Renal Allograft - a 12 Months Protocol Biopsy Study.

Author: Severova-Andreevska G, Grcevska L, Petrushevska G, Cakalaroski K, Sikole A, Stojceva-Taneva O, Danilovska I, and Ivanovski N
Abstract: Introduction: Renal transplantation became a routine and successful medical treatment for Chronic Kidney Disease in the last 30 years all over the world. Introduction of Luminex based Single Antigen Beads (SAB) and recent BANFF consensus of histopathological phenotypes of different forms of rejection enables more precise diagnosis and changes the therapeutic approach. The graft biopsies, protocol or cause, indicated, remain a golden diagnostic tool for clinical follow up of kidney transplant recipients (KTR)., Aim: The study aimed to analyse the histopathological changes in renal grafts 12 months after the surgery in KTR with satisfactory kidney function., Material and Methods: A 12-month protocol biopsy study was performed in a cohort of 50 Kidney transplant recipients (42 from living and 8 from deceased donors). Usual work-up for suitable donors and recipients, standard surgical procedure, basic principles of peri and postoperative care and follow up were done in all KTR. Sequential quadruple immunosuppression including induction with Anti-thymocyte globulin (ATG) or Interleukin-2R antagonist (IL-2R), and triple drug maintenance therapy with Calcineurin Inhibitors (CNI), Mycophenolate Mofetil (MMF) and Steroids were prescribed to all pts. Different forms of Glomerulonephritis (16), Hypertension (10), End Stage Renal Disease (13), Hereditary Nephropathies (6), Diabetes (3) and Vesicoureteral Reflux (2) were the underlying diseases. All biopsies were performed under ultrasound guidance. The 16 gauge needles with automated "gun" were used to take 2 cores of tissue. The samples were stained with HE, PAS, Trichrome Masson and Silver and reviewed by the same pathologist. A revised and uploaded BANFF 2013 classification in 6 categories (Cat) was used., Results: Out of 48 biopsies, 15 (31%) were considered as normal, 4 (8%), Borderline (BL-Cat 3), 5 (10%) as Interstitial Fibrosis/Tubular Atrophy (IF/TA-Cat 5), 5 (10%) were classified as non-immunological (Cat 6), 2 as a pure antibody-mediated rejection (ABMR-Cat 2) and T-cell Mediated Rejection (TCMR-Cat 4). The remaining 17 samples were classified as a "mixed" rejection: 7 (41%) ABMR + IF/TA, 5 (29%) ABMR + BL + IF/TA, 2 (11%) BL + IF/TA, 1 (5%) ABMR + BL, 1 (5%) ABMR + TCMR and 1 (5%) TCMR + IF/TA. The mean serum creatinine at the time of the biopsy was 126.7 ± 23.4 µmol/L, while GFR-MDRD 63.4 ± 20.7 ml/min, which means that the majority of the findings were subclinical. Among the non-immunological histological findings (Cat 6), 3 cases belonged to CNI toxicity, 1 to BK nephropathy and 1 to recurrence of the primary disease., Conclusion: Our 12-month protocol biopsy study revealed the presence of different forms of mixed subclinical rejection. Use of recent BANFF classification and scoring system enables more precise diagnosis and subsequently different approach to the further treatment of the KTR. More correlative long-term studies including Anti HLA antibodies and Endothelial Cell Activation- Associated Transcripts (ENDAT) are needed.
Published: 2018
Full Text: View/download PDF

40. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary.

Author: Kramer A, Pippias M, Noordzij M, Stel VS, Afentakis N, Ambühl PM, Andrusev AM, Fuster EA, Arribas Monzón FE, Åsberg A, Barbullushi M, Bonthuis M, Caskey FJ, Castro de la Nuez P, Cernevskis H, des Grottes JM, Garneata L, Golan E, Hemmelder MH, Ioannou K, Jarraya F, Kolesnyk M, Komissarov K, Lassalle M, Macario F, Mahillo-Duran B, Martín de Francisco AL, Palsson R, Pechter Ü, Resic H, Rutkowski B, Santiuste de Pablos C, Seyahi N, Simic Ogrizovic S, Slon Roblero MF, Spustova V, Stojceva-Taneva O, Traynor J, Massy ZA, and Jager KJ
Abstract: Background: This article summarizes the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry's 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2015 within 36 countries., Methods: In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015, from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined., Results: In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients, peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish region of Cantabria. For patients commencing RRT during 2006-10, the 5-year unadjusted patient survival probabilities on all RRT modalities combined was 50.0% (95% confidence interval 49.9-50.1).
Published: 2018
Full Text: View/download PDF

41. Hypomagnesemia and cause-specific mortality in hemodialysis patients: 5-year follow-up analysis.

Author: Selim GN, Spasovski G, Tozija L, Georgievska-Ismail L, Zafirova-Ivanovska B, Masin-Spasovska J, Rambabova-Busletic I, Petronijevic Z, Dzekova-Vidimliski P, Ristovska V, Pusevski V, and Stojceva-Taneva O
Subjects: Aged, C-Reactive Protein metabolism, Cardiovascular Diseases blood, Cardiovascular Diseases mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multivariate Analysis, Natriuretic Peptide, Brain blood, Proportional Hazards Models, Prospective Studies, Renal Insufficiency, Chronic therapy, Risk Factors, Magnesium blood, Renal Dialysis, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic mortality
Abstract: Introduction: The aim of this prospective study was to evaluate the association between serum magnesium (Mg) and mortality, in particular the cause-specific mortality of Mg and other risk factors in hemodialysis (HD) patients., Methods: We studied a cohort of 185 HD patients receiving thrice-weekly HD treatment, on a dialysate Mg concentration of 0.5 mmol/L. We stratified 3 patient groups according to the level of Mg: lower (<1.1 mmol/L), intermediate-reference (1.1 to <1.3 mmol/L), and higher (Mg >1.3 mm/L)., Results: During the 5-year follow-up, 60 patients died, with cardiovascular (CV) disease as the predominant cause (73.3%). Hazard ratio (HR) for all-cause and CV mortality were 2.55 and 2.67 in the lower versus intermediate Mg group, but there was no significant association between the higher and intermediate Mg group. Univariate Cox regression analysis showed that Mg <1.1 versus 1.1-1.30 mml/L with HR 2.34, was a significant univariate predictor for increased mortality in addition to the Hb <110 g/L, Alb <40 g/L, C-reactive protein (CRP) ≥10 mg/L and brain natriuretic peptide >1,200 pg/mL. However, in the multivariate analysis only CRP ≥10 mg/L with HR 3.89 was a significant predictor of mortality. Subgroup analyses showed that among patients with CRP >10 mg/L, HR for all-cause and CV mortality of the lower versus intermediate Mg group were 1.96 and 2.39, respectively, not reaching significance for the higher versus intermediate Mg group. Conversely, there was no association between Mg level and all-cause and CV mortality within these 3 groups among patients with CRP <10 mg/L., Conclusions: Lower serum Mg level was significantly associated with an increased all-cause and cardiovascular mortality in HD patients, especially in inflamed patients.
Published: 2017
Full Text: View/download PDF

42. The European Renal Association - European Dialysis and Transplant Association Registry Annual Report 2014: a summary.

Author: Pippias M, Kramer A, Noordzij M, Afentakis N, Alonso de la Torre R, Ambühl PM, Aparicio Madre MI, Arribas Monzón F, Åsberg A, Bonthuis M, Bouzas Caamaño E, Bubic I, Caskey FJ, Castro de la Nuez P, Cernevskis H, de Los Ángeles Garcia Bazaga M, des Grottes JM, Fernández González R, Ferrer-Alamar M, Finne P, Garneata L, Golan E, Heaf JG, Hemmelder MH, Idrizi A, Ioannou K, Jarraya F, Kantaria N, Kolesnyk M, Kramar R, Lassalle M, Lezaic VV, Lopot F, Macario F, Magaz Á, Martín de Francisco AL, Martín Escobar E, Martínez Castelao A, Metcalfe W, Moreno Alia I, Nordio M, Ots-Rosenberg M, Palsson R, Ratkovic M, Resic H, Rutkowski B, Santiuste de Pablos C, Seyahi N, Fernanda Slon Roblero M, Spustova V, Stas KJF, Stendahl ME, Stojceva-Taneva O, Vazelov E, Ziginskiene E, Massy Z, Jager KJ, and Stel VS
Abstract: Background: This article summarizes the European Renal Association - European Dialysis and Transplant Association Registry's 2014 annual report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2014 within 35 countries. Methods: In 2016, the ERA-EDTA Registry received data on patients who in 2014 where undergoing RRT for ESRD, from 51 national or regional renal registries. Thirty-two registries provided individual patient level data and 19 provided aggregated patient level data. The incidence, prevalence and survival probabilities of these patients were determined. Results: In 2014, 70 953 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 133 per million population (pmp). The incidence ranged by 10-fold; from 23 pmp in the Ukraine to 237 pmp in Portugal. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. By day 91 of commencing RRT, 81% of patients were receiving haemodialysis. On 31 December 2014, 490 743 individuals were receiving RRT for ESRD, equating to an unadjusted prevalence of 924 pmp. This ranged throughout Europe by more than 10-fold, from 157 pmp in the Ukraine to 1794 pmp in Portugal. In 2014, 19 406 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 36 pmp. Again this varied considerably throughout Europe. For patients commencing RRT during 2005-09, the 5-year-adjusted patient survival probabilities on all RRT modalities was 63.3% (95% confidence interval 63.0-63.6). The expected remaining lifetime of a 20- to 24-year-old patient with ESRD receiving dialysis or living with a kidney transplant was 21.9 and 44.0 years, respectively. This was substantially lower than the 61.8 years of expected remaining lifetime of a 20-year-old patient without ESRD.
Published: 2017
Full Text: View/download PDF

43. Clinical Effects of Standard and Individualized Dialysate Sodium in Patients on Maintenance Hemodialysis.

Author: Eftimovska-Otovic N, Stojceva-Taneva O, Grozdanovski R, and Stojcev S
Abstract: Background: The degree to which the dialysate prescription and, in particular, the dialysate sodium concentration influences blood pressure and interdialytic weight gain (IDWG) via changes in sodium flux, plasma volume or the other parameters is not well understood. The aim of the study was to investigate whether dialysis patients will have some beneficial effects of dialysate sodium set up according to serum sodium or sodium modeling., Material and Methods: Ninety-two nondiabetic subjects (52 men and 40 women) performed 12 consecutive hemodialysis (HD) sessions (4 weeks) with dialysate sodium concentration set up on 138 mmol/L (standard sodium - first phase), followed by 24 sessions (second phase) wherein dialysate sodium was set up according to individualized sodium. Variables of interest were: systolic, diastolic and mean blood pressure, pulse, IDWG, thirst score - (Xerostomia Inventory (XI) and Dialysis Thirst Inventory (DTI)) and side effects (occurrence of hypotension and muscle cramps). After the first phase, the subjects were divided into 3 groups: normotensive (N=76), hypertensive (N= 11) and hypotensive (N=5) based on the average pre-HD systolic BP during the whole period of the first phase., Results: Sodium individualization resulted in significantly lower blood pressure (133.61 ± 11.88 versus 153.60 ± 14.26 mmHg; p=0.000) and IDWG (2.21 ± 0.93 versus 1.87 ± 0.92 kg; p=0.018) in hypertensive patients, whereas normotensive patients showed only significant decrease in IDWG (2.21 ± 0.72 versus 2.06 ± 0.65, p=0,004). Sodium profiling in hypotensive patients significantly increased IDWG (2.45 vs. 2.74, p= 0,006), and had no impact on blood pressure. Thirst score was significantly lower in normotensive patients with individualized-sodium HD and showed no change in the other two groups. During the second phase, hypotension occurred in only 1 case and muscle cramps in 10 normotensive patients., Conclusion: Individualized sodium resulted in clinical benefits in normotensive and hypertensive patients.
Published: 2016
Full Text: View/download PDF

44. Hypercalcemia as a Cause of Kidney Failure: Case Report.

Author: Stojceva-Taneva O, Taneva B, and Selim G
Abstract: Background: Hypercalcemia is a common manifestation in clinical practice and occurs as a result of primary hyperparathyroidism, malignancy, milk-alkali syndrome, hyper or hypothyroidism, sarcoidosis and other known and unknown causes. Patients with milk-alkali syndrome typically are presented with renal failure, hypercalcemia, and metabolic alkalosis caused by the ingestion of calcium and absorbable alkali. This syndrome is caused by high intake of milk and sodium bicarbonate., Case Presentation: We present a 28-year old male admitted to hospital with a one-month history of nausea, vomiting, epigastric pain, increased blood pressure and worsening of renal function with hypercalcemia. His serum PTH level was almost undetectable; he had mild alkalosis, renal failure with eGFR of 42 ml/min, anemia, hypertension and abnormal ECG with shortened QT interval and ST elevation in V1-V4. He had a positive medical history for calcium-containing antacids intake and after ruling out primary hyperparathyroidism, malignancy, multiple myelomas, sarcoidosis, and thyroid dysfunction, it seemed plausible to diagnose him as having the milk-alkali syndrome., Conclusion: Although milk-alkali syndrome currently may be more probably a result of calcium and vitamin D intake in postmenopausal women, or in elderly men with reduced kidney function taking calcium-containing medications, one should not exclude the possibility of its appearance in younger patients taking calcium-containing medications and consider it a serious condition taking into account its possibility of inducing renal insufficiency.
Published: 2016
Full Text: View/download PDF

45. Prevalence of Diabetes Mellitus in Patients with Chronic Kidney Disease.

Author: Stojceva-Taneva O, Otovic NE, and Taneva B
Abstract: Background: Chronic kidney disease (CKD) became a new epidemic of the twentieth and twenty-first centuries. Diabetic nephropathy is one of the leading causes of end-stage renal failure as a result of the diabetes epidemic worldwide., Aim: The aim of our study was to assess the prevalence of CKD in the Republic of Macedonia and its association with diabetes mellitus., Materials and Methods: The study was a part of a study conducted in 2006 in terms of screening for early detection of kidney disease. It was a cross-sectional study based on a random sample of patients aged > 20, consecutively consulting their primary physician for any cause. Fifty physicians throughout the country were included in the study. A total of 2637 patients have been analyzed based on integrity data. GFR was estimated using corrected values of serum creatinine and calculating kidney function by the Cockroft & Gault formula, adjusted for body surface using the Gehan & George formula. Patients with estimated glomerular filtration rate (eGFR) less than 60 ml/min were considered as having CKD. Blood pressure, body weight, height, serum creatinine, glucose, hemoglobin, hematocrit, urinalysis and medical history for presence of cardiovascular diseases or diabetes were also assessed., Results: The mean age of the subjects was 45.97 ± 16.55 SD and 17.97% were older than 60. Regarding gender, 44.14% were males. The prevalence of diabetes mellitus was 13.9%. Subjects with CKD (eGFR less than 60 ml/min) were 7.53% of the total. Subjects aged 60 or above, had 20 times higher risk of having CKD (eGFR less than 60 ml/min/1.73 m(2)). Out of the total group of subjects, 13.9% had diabetes mellitus and they had 3.13 times higher risk of having CKD stage 3-5 (eGFR less than 60 ml/min/1.73 m(2)) when compared to non-diabetics. The results showed that diabetes was significantly more associated with lower eGFR (less than 60 ml/min/1.73 m(2)) in younger subjects (age less than 60) compared to older ones (odds ratio 3.29 versus 1.21)., Conclusion: Our study showed that chronic kidney disease is frequent in the Republic of Macedonia and is associated with older age and diabetes. Diabetes had a significantly stronger association with CKD at younger age.
Published: 2016
Full Text: View/download PDF

46. Clinical Characteristics of Patients with Intradialytic Hypertension.

Author: Eftimovska-Otovic N, Grozdanovski R, Taneva B, and Stojceva-Taneva O
Subjects: Adult, Age Factors, Aged, Biomarkers blood, Body Mass Index, Case-Control Studies, Female, Humans, Hypertension diagnosis, Hypertension mortality, Hypertension physiopathology, Hyponatremia blood, Hyponatremia epidemiology, Male, Middle Aged, Prevalence, Renal Dialysis methods, Renal Dialysis mortality, Republic of North Macedonia epidemiology, Risk Factors, Sodium blood, Time Factors, Blood Pressure, Hypertension epidemiology, Renal Dialysis adverse effects
Abstract: Introduction: Intradialytic hypertension with a prevalence of 15% among hemodialysis patients is with unknown pathophysiology, demographic, laboratoiy and clinical characteristic of patients, and it's influence on longtenn clinical effects (cardiovascular morbidity and mortality, rate of hospitalization). The aim of the study is to present the clinical, laboratoiy and demographic characteristics of patients with intradialytic hypertension in our dialysis center., Materials and Methods: Out of 110 hemodialysis patients, 17 patients (15,45%) had intradialytic hypertension - started at a systolic pressure greater than 140 nun Hg or had an increase in systolic pressure more than 10 mm Hg during the session, and 17 patients were nonnotensive or had a drop in blood pressure dining the dialysis. HD were performed 3 times per week with a duration of 4-5 hours, on machines with controlled ultrafiltration and high flux syntetic membrane (polyetersulfon) sterilized with gamma rays. A dialysate with standard electrolytes content was used (Na(+) 138 mmol/L, K(+) 2,0 mmol/L, Ca(++) 1,5 mmol/L, Mg (+)1,0 mmol/L, CH(3)COO(-) 3,0 mmol/L, Cl -110 mmol/1, HCO(3)(-) 35 mmol/L). We analysed the following demographic and clinical characteristics: gender, age, BMI, dialysis vintage, vascular acces, cardiovascular comorbidity (cardiomyopathy, ischemic cardiac disease, peripheral artery disease, heart valve disease), number and type of antihypertensive drugs, weekly dose of erythropoesis - stimulating agent, standard monthly, three and six months laboratoiy analyzes, and sp Kt/V and PCR. Statistical analysis was performed using the statistical software SPSS 17.0., Results: hi both groups men were predominant (IDH group 88.23%, control group 64.07%). The IDH group was older (59.00 ± 7.64 versus 49.00 ± 13.91, p = 0.314) and with lower BMI (p = 0.246) compared to the control group. The DDH patients had significantly lower serum sodium and higher sodium gradient (135.75 ± 2.03 versus 137.33 ± 1.97, p = 0.042; 2.25 ± 1.98 versus 0.66 ± 1.44, p = 0.0267, respestively). All other laboratoiy findings showed no statistically significant differences between the two groups. The IDH group had significantly higher interdialysis weight gain and less effective ultrafiltration individually at each dialysis session compared to the control group (2.23 ± 0.866 versus 2.37 ± 0.69, p = 0.011; 3.87 ± 1,26 versus 3.56 ± 1.18, p = 0.025, respectively). The systolic and mean arterial pressure after the HD were statistically higher in the IDH group., Conclusion: Older age, lower BMI, borderline hyponatremia, higher sodium gradient and smaller ultrafiltration rate are the clinical characteristics of patients with intradialytic hypertension.
Published: 2015
Full Text: View/download PDF

47. Momir H. Polenakovic - Founder of the Nephrology Associations in the Republic of Macedonia.

Author: Spasovski G and Stojceva-Taneva O
Subjects: Biomedical Research education, Education, Medical history, History, 20th Century, History, 21st Century, Humans, Kidney Diseases diagnosis, Kidney Diseases therapy, Nephrology education, Republic of North Macedonia, Biomedical Research history, Kidney Diseases history, Nephrology history, Societies, Medical history
Abstract: Acad. Momir Polenakovic has devoted his life and work in the diagnosis and treatment of kidney patients, as well as in research of kidney disease. The great experience he has acquired in the work with kidney patients, and after the visit to the most renowned nephrology centers in Europe and the world, he has transferred it to his colleagues through the work in the medical and nephrology associations. The work of the associations was in fact a successful education of young doctors and specialists. Among his most distinguished positions, we can mention: President of the Macedonian Medical Association, founder and President of the MSNDTAO, President of the Yugoslav Society of Nephrology, founder and President of BANTAO, as well as member of the Boards of ESAO and ERA-EDTA. He has received a lot of recognitions for his work achievements.
Published: 2015
Full Text: View/download PDF

48. Timing of nephrology referral and initiation of dialysis as predictors for survival in hemodialysis patients: 5-year follow-up analysis.

Author: Selim G, Stojceva-Taneva O, Spasovski G, Tozija L, Grozdanovski R, Georgievska-Ismail L, Zafirova-Ivanovska B, Dzekova P, Trajceska L, Gelev S, Mladenovska D, and Sikole A
Subjects: Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases mortality, Cause of Death, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nephrology, Proportional Hazards Models, Retrospective Studies, Survival Rate, Time Factors, Young Adult, Kidney Failure, Chronic mortality, Kidney Failure, Chronic therapy, Referral and Consultation, Renal Dialysis
Abstract: Background: A consensus about the optimal timing of dialysis initiation is still controversial. Thus, the goal of this analysis was to compare outcomes in patients with early and late referral with early and late initiation of hemodialysis (HD)., Methods: We studied 190 patients (mean age 52.03±14.22) who were initiated on HD between 1994 and 2004. Patients who received regular nephrology care during 12 months before HD initiation were categorized as early referrals (ER) and those without nephrology care were late referrals (LR). The early start (E-start) was defined by the estimated GFR (eGFR) at start of HD≥7.5 mL/min/1.73 m2, and the late start (L-start) by eGFR of <7.5 mL/min/1.73 m2. The four groups of patients (ER with E-start and L-start; LR with E-start and L-start) were prospectively followed in the next 60 months after HD initiation., Results: During the follow-up, 43.3% of E-start and 43.2% of L-start patients died, without significant difference in survival between the groups [HR for L-start vs. E-start=1.06 (95% CI 0.69-1.62); p=0.797]. When survival between ER and LR groups was compared (28.1% patients in the ER and 53.2% in the LR died), there was significant difference in survival [HR for LR vs. ER=2.16 (95% CI 1.28-3.65); p=0.004]. Compared with patients with ER and L-start, higher mortality was observed among those with LR and L-start [HR 3.51 (95% CI 1.48-8.35); p=0.004] and LR with E-start [HR 2.79 (95% CI 1.16-6.7); p=0.022]. There was no significant difference between patients in ER with L-start and ER with E-start., Conclusions: Our study showed that ER above 12 months before HD initiation and L-start of dialysis was associated with a reduced mortality risk in HD patients.
Published: 2015
Full Text: View/download PDF

49. Use of vascular access for haemodialysis in Europe: a report from the ERA-EDTA Registry.

Author: Noordzij M, Jager KJ, van der Veer SN, Kramar R, Collart F, Heaf JG, Stojceva-Taneva O, Leivestad T, Buturovic-Ponikvar J, Benítez Sánchez M, Moreso F, Prütz KG, Severn A, Wanner C, Vanholder R, and Ravani P
Subjects: Adult, Aged, Aged, 80 and over, Europe epidemiology, Female, Humans, Incidence, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic mortality, Logistic Models, Male, Middle Aged, Prevalence, Prognosis, Registries, Survival Rate, Young Adult, Arteriovenous Shunt, Surgical trends, Catheterization, Central Venous trends, Catheters, Indwelling statistics & numerical data, Kidney Failure, Chronic therapy, Practice Patterns, Physicians' trends, Renal Dialysis
Abstract: Background: Although arteriovenous fistulas (AVFs) are actively promoted, their use at the start of haemodialysis (HD) seems to be decreasing worldwide. In this paper, we describe recent trends in incidence and prevalence of vascular access types in Europe from 2005 to 2009 and their relationship with patient characteristics and survival., Methods: Ten European renal registries participating in the ERA-EDTA Registry provided data on incidence (n = 13,044) and/or prevalence (n = 75,715) of vascular access types. We used logistic regression to assess which factors influence the likelihood to be treated with an AVF rather than another type., Results: The use of AVFs at the start of HD showed a significant decreasing trend from 42% in 2005 to 32% in 2009 (P < 0.0001), while the use of central venous catheters (CVCs) increased from 58 to 68% (P < 0.0001). A similar evolution pattern was observed for the prevalence; use of AVFs decreased from 66 to 62% and use of CVCs increased from 28 to 32%. There was a large international variation in the use of the different vascular access types. Female patients [adjusted odds ratio: 0.84, 95% confidence interval (CI): 0.78-0.90] and those ≥80 years (0.77, 95% CI: 0.67-0.90) were least likely to start HD with an AVF., Conclusion: In Europe, there is a decreasing trend in the use of AVFs and an increasing trend in the use of CVCs at the start and after the start of HD. We cannot explain all between-country variations we found, and more research is needed to clarify how healthcare around vascular access is organized in Europe., (© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
Published: 2014
Full Text: View/download PDF

50. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Author: Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, and Jankowski J
Subjects: Adult, Aged, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 urine, Diabetic Nephropathies diagnosis, Diabetic Nephropathies etiology, Diagnosis, Differential, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies urine, Peptidomimetics urine, Proteomics methods
Abstract: Background: Diabetic nephropathy (DN) is one of the major late complications of diabetes. Treatment aimed at slowing down the progression of DN is available but methods for early and definitive detection of DN progression are currently lacking. The 'Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria trial' (PRIORITY) aims to evaluate the early detection of DN in patients with type 2 diabetes (T2D) using a urinary proteome-based classifier (CKD273)., Methods: In this ancillary study of the recently initiated PRIORITY trial we aimed to validate for the first time the CKD273 classifier in a multicentre (9 different institutions providing samples from 165 T2D patients) prospective setting. In addition we also investigated the influence of sample containers, age and gender on the CKD273 classifier., Results: We observed a high consistency of the CKD273 classification scores across the different centres with areas under the curves ranging from 0.95 to 1.00. The classifier was independent of age (range tested 16-89 years) and gender. Furthermore, the use of different urine storage containers did not affect the classification scores. Analysis of the distribution of the individual peptides of the classifier over the nine different centres showed that fragments of blood-derived and extracellular matrix proteins were the most consistently found., Conclusion: We provide for the first time validation of this urinary proteome-based classifier in a multicentre prospective setting and show the suitability of the CKD273 classifier to be used in the PRIORITY trial., (© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
Published: 2014
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

87 results on '"Stojceva-Taneva O"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources